Supporting Information

Copper-Catalyzed Carbonylative Multi-Component Borylamidation of Alkenes for Synthesizing γ -Boryl Amides with CO as both Methylene and Carbonyl Sources

Hui-Qing Geng,^[a] Yan-Hua Zhao,^[a] Peng Yang^[a] and Xiao-Feng Wu* ^[a,b]

[a] Leibniz-Institut für Katalyse e.V., Albert-Einstein-Straße 29a, 18059 Rostock (Germany).

[b] Dalian National Laboratory for Clean Energy, Dalian Institute of Chemical Physics, Chinese Academy of

Sciences, 116023, Dalian, Liaoning, China, E-mail: xwu2020@dicp.ac.cn

Table of Contents

1. Genernal information	S2
2. Optimization of reaction conditions.	S2
3. General procedure.	S6
3.1 General procedure for primary amines	S6
3.2 General procedure for secondary amines-hydrochloride	S7
3.3 Failed examples	S7
4. Characterization Data.	S8
5. Derivatization of 1a.	. S31
5.1 Oxidation of 1a	. S31
5.2 Vinylation of 1a	. S32
5.3 Preparation of trifluoroboration salt of 1a.	. S32
5.4 <i>N</i> -Arylation of 1a	
6. Mechanism studies.	
6.1 ¹³ C labeling experiment	
6.2 Deuterium labeling experiment.	. S36
6.2.1 Deuterated <i>trans-β</i> -methylstyrene.	. S36
6.2.2 DMSO- <i>d</i> ₆	. S39
6.2.3 Aniline- <i>d</i> ₇	
6.2.4 Quenching with D ₂ O.	
6.2.5 Additional D ₂ O	. S48
6.2.6 Mixed deuterated reagents of aniline- d_7 and DMSO- d_6 .	. S52
6.2.7 Mixed deuterated reagents of aniline- d_7 , DMSO- d_6 , and D ₂ O.	
7. X-ray crystal analysis of 1a.	. S57
8. References.	
9. NMR spectra	. S61

1. General information

All experiments were carried out under a carbon monoxide or nitrogen atmosphere, unless otherwise stated. All chemical reagents were purchased from Sigma-Aldrich, TCI, abcr GmbH Germany, and BLD pharm of the highest purity grade and used without purification. In addition, B₂Pin₂ and NAOEt are stored in the glove box. Internal aryl olefins were prepared according to previous references. All solvents were dried by standard techniques. Silica gel column chromatography was carried out using silica gel (200-300 mesh). n-Pentane and ethyl acetate were used as eluent. Analytical thin layer chromatography (TLC) was performed on silica gel (silica gel 60 DC-Platten ALUGRAM[®] Xtra SIL G / UV₂₅₄). TLC plates were visualized with UV light, and/or submersion in KMnO₄ solution and/or phosphomolybdic acid. Bruker Avance III HD 300 NMR (¹H, 300 MHz; ${}^{13}C{}^{1}H$, 75 MHz; ${}^{11}B$, 96 MHz), and Bruker ARX 400 NMR spectrometers (${}^{1}H$, 400 MHz; ${}^{13}C{}^{1}H{}$, 101 MHz) recorded all NMR spectra. The chemical shifts are reported as δ values relative to internal chloroform (δ 7.26 for ¹H NMR) and TMS (δ 0.00 for ¹H NMR) chloroform (δ 77.16 for ¹³C{¹H} NMR) in parts per million (ppm). The following abbreviations are used for the NMR spectra' multiplicities: s: singlet, d: doublet, dd: doublet of doublet, t: triplet, q: quartet, m: multiplet, and br: broad signal for proton spectra. All ¹³C NMR spectra were broad-band ¹H decoupled. However, it is hard to observe the signals for the carbon attached to boron in the ¹³C{¹H} NMR spectra. Gas chromatography (GC) analyses were performed on an Agilent HP-7890A instrument with an FID detector and HP-5 capillary column (polydimethylsiloxane with 5% phenyl groups, 30 m, 0.32 mm i.d. 0.25 µm film thickness) using argon as carrier gas. High-resolution mass spectra were recorded on an Agilent 6210 system. All the reactions which used CO were performed in an autoclave. The laboratory should be wellequipped with a CO detector and alarm system.

2. Optimization of reaction conditions.

Table S1. Screening of ligand

Ph + B_2Pin_2 + $PhNH_2$ 0.2 mmol 2.5 equiv. 2.5 equiv.	Cul (5 mol%) Ligand (5 mol%) NaO ^t Bu (2.5 equiv.) CO (10 bar) DMAc (1 mL) 60 °C, 20 h	O V_Ph H
Entry	Base	1a (%)
1	DPPE	24
2	DPPB	8
3	DPPP	11
4	DPPPe	n.d.
5	DPPBz	13
6	Xantphos	n.d.
7	DPPM	n.d.

Reaction conditions: (*E*)-prop-1-en-1-ylbenzene (0.2 mmol), CuI (5 mol%), Ligand (5 mol%), NaO'Bu (2.5 equiv.), B₂Pin₂ (2.5 equiv.), PhNH₂ (2.5 equiv.), DMAc (1 mL), CO (10 bar), 60 °C, 20 h; Yields are determined by GC with hexadecane as an internal standard; n.d.: not detected.

Table S2. Screening of solvent

Ph + B_2Pin_2 + PhNH ₂ 0.2 mmol 2.5 equiv. 2.5 equiv.	Cul (5 mol%) DPPE (5 mol%) NaO'Bu (2.5 equiv.) CO (10 bar) Solvent (1 mL) 60 °C, 20 h Ph ^{'''} O Ph ^{''''} O Ph ^{''''} O H	
Entry	Solvent	1a (%)
1	DMF	21
2	DMSO	68
3	NMP	11
4	Toluene	n.d.
5	THF	33
6	CH ₃ CN	n.d.

Reaction conditions: (*E*)-prop-1-en-1-ylbenzene (0.2 mmol), CuI (5 mol%), DPPE (5 mol%), NaO'Bu (2.5 equiv.), B₂Pin₂ (2.5 equiv.), PhNH₂ (2.5 equiv.), solvent (1 mL), CO (10 bar), 60 °C, 20 h; Yields are determined by GC with hexadecane as an internal standard; n.d.: not detected.

Table S3. Screening of copper catalyst

Ph + B_2Pin_2 + PhNH ₂ 0.2 mmol 2.5 equiv. 2.5 equiv.	[Cu] (5 mol%) DPPE (5 mol%) NaO ^f Bu (2.5 equiv.) CO (10 bar) DMSO (1 mL) 60 °C, 20 h Ia	
Entry	Solvent	1a (%)
1	CuCl ₂	54
2	Cu(OTf) ₂	13
3	CuCN	4
4	CuSO ₄	n.d.
5	CuI	68
6	$CuBr_2$	10
7	CuBr•Me ₂ S	Trace
8	CuBr	Trace
9	Cu(OAc) ₂	69
10	IPrCuCl	Trace
11	IPrCuCl (w/o DPPE)	Trace
12	IMesCuCl	6
13	IMesCuCl (w/o DPPE)	Trace

Reaction conditions: (*E*)-prop-1-en-1-ylbenzene (0.2 mmol), [Cu] (5 mol%), DPPE (5 mol%), NaO'Bu (2.5 equiv.), B₂Pin₂ (2.5 equiv.), PhNH₂ (2.5 equiv.), DMSO (1 mL), CO (10 bar), 60 °C, 20 h; Yields are determined by GC with hexadecane as an internal standard; n.d.: not detected.

Table S4. Screening of the base

	$\begin{array}{c} Cu(OAc)_{2} (5 \text{ mol\%}) \\ DPPE (5 \text{ mol\%}) \\ Base (2.75 \text{ equiv.}) \\ \hline \\ 0.2 \text{ mmol} 2.5 \text{ equiv.} 2.5 \text{ equiv.} \\ \hline \\ 0.2 \text{ mmol} 2.5 \text{ equiv.} 2.5 \text{ equiv.} \\ \hline \\ 0.2 \text{ mmol} 1a \end{array}$,∠Ph I
Entry	Base	1a (%)
1	NaO'Bu	69
2	LiO'Bu	41
3	KO'Bu	Trace
4	NaOEt	74
5	Cs ₂ CO ₃	11
6	LiOMe	Trace
7	KOMe	17

Reaction conditions: (*E*)-prop-1-en-1-ylbenzene (0.2 mmol), Cu(OAc)₂ (5 mol%), DPPE (5 mol%), base (2.5 equiv.), B₂Pin₂ (2.5 equiv.), PhNH₂ (2.5 equiv.), DMSO (1 mL), CO (10 bar), 60 °C, 20 h; Yields are determined by GC with hexadecane as an internal standard.

Table S5. Screening of the amount of catalytic system

	Ph + B_2Pin_2 + $PhNH_2$	Cu(OAc) ₂ (x mol%) DPPE (y mol%) NaOEt (2.75 equiv.)	
	0.2 mmol 2.5 equiv. 2.5 equiv.	CO (10 bar) DMSO (1 mL) 60 °C, 20 h H 1a	
Entry	Cu(OAc) ₂	DPPE	1a (%)
1	2.5 mol%	2.5 mol%	66
2	5 mol%	5 mol%	74
3	7.5 mol%	7.5 mol%	56
4	10 mol%	10 mol%	60
5	5 mol%	7.5 mol%	49
6	5 mol%	10 mol%	32

Reaction conditions: (*E*)-prop-1-en-1-ylbenzene (0.2 mmol), Cu(OAc)₂ (x mol%), DPPE (y mol%), NaOEt (2.5 equiv.), B₂Pin₂ (2.5 equiv.), PhNH₂ (2.5 equiv.), DMSO (1 mL), CO (10 bar), 60 °C, 20 h; Yields are determined by GC with hexadecane as an internal standard.

Table S6. Screening of the amount of B2pin2

	$\begin{array}{c} Cu(OAc)_2 (5 \text{ mol}\%) \\ DPPE (5 \text{ mol}\%) \\ DPPE (5 \text{ mol}\%) \\ NaOEt (2.75 \text{ equiv.}) \\ \hline \\ 0.2 \text{ mmol} \\ 2.5 \text{ equiv.} \\ \hline \\ 0.2 \text{ mmol} \\ 2.5 \text{ equiv.} \\ \hline \\ 0 \text{ of } \text{ c}, 20 \text{ h} \\ \hline \\ 1a \end{array}$, Ph
Entry	B ₂ pin ₂	1a (%)
1	3.0 eq.	71
2	3.5 eq.	79
3	3.75 eq.	73
4	4.0 eq.	68

Reaction conditions: (*E*)-prop-1-en-1-ylbenzene (0.2 mmol), Cu(OAc)₂ (5 mol%), DPPE (5 mol%), NaOEt (2.5 equiv.), B₂Pin₂ (x equiv.), PhNH₂ (2.5 equiv.), DMSO (1 mL), CO (10 bar), 60 °C, 20 h; Yields are determined by GC with hexadecane as an internal standard.

Table S7. Screening of the amount of PhNH₂

	Ph + B_2Pin_2 + PhNH ₂	Cu(OAc) ₂ (5 mol%) DPPE (5 mol%) NaOEt (2.75 equiv.)	Bpin J ^{"""} O	
	0.2 mmol 3.5 equiv.	CO (10 bar) DMSO (1 mL) 60 °C, 20 h	Ph ^{```} N ^{Ph} H 1a	
Entry		PhNH ₂		1a (%)
1		1.5 eq.		64
2		1.75 eq		70
3		2.0 eq.		75
4		2.5 eq.		79
5	2	2.75 eq.		74

Reaction conditions: (*E*)-prop-1-en-1-ylbenzene (0.2 mmol), Cu(OAc)₂ (5 mol%), DPPE (5 mol%), NaOEt (2.5 equiv.), B₂Pin₂ (3.5 equiv.), PhNH₂ (x equiv.), DMSO (1 mL), CO (10 bar), 60 °C, 20 h; Yields are determined by GC with hexadecane as an internal standard.

	$\begin{array}{c} Cu(OAc)_2 (5 \text{ mol}\%) \\ DPPE (5 \text{ mol}\%) \\ DPPE (5 \text{ mol}\%) \\ NaOEt (2.75 \text{ equiv.}) \\ 0.2 \text{ mmol} 3.5 \text{ equiv.} 2.5 \text{ equiv.} \\ X \ ^\circ C, 20 \text{ h} \end{array} \xrightarrow{\text{Cu}(OAc)_2 (5 \text{ mol}\%) \\ DPPE (5 \text{ mol}\%) \\ DROEt (2.75 \text{ equiv.}) \\ CO (10 \text{ bar}) \\ DMSO (1 \text{ mL}) \\ X \ ^\circ C, 20 \text{ h} \end{array} \xrightarrow{\text{Bpin}} \xrightarrow{\text{With}} \xrightarrow{\text{H}} \xrightarrow{\text{H}} \xrightarrow{\text{H}}$	'n
Entry	Temperature	1a (%)
1	r.t.	38
2	80 °C	44
3	100 °C	25

Table S8. Screening of the temperature

Reaction conditions: (*E*)-prop-1-en-1-ylbenzene (0.2 mmol), Cu(OAc)₂ (5 mol%), DPPE (5 mol%), NaOEt (2.75 equiv.), B₂Pin₂ (3.5 equiv.), PhNH₂ (2.5 equiv.), DMSO (1 mL), CO (10 bar), x °C, 20 h; Yields are determined by GC with hexadecane as an internal standard.


	Ph + B_2Pin_2 + $Cy_2NH \bullet HCI$ 0.2 mmol 3.5 equiv.	Cu(OAc) ₂ (5 mol%) DPPE (5 mol%) NaOEt (2.75 equiv.) CO (10 bar) DMSO (1 mL) 60 °C, 20 h	Bpin Ph ^{''''} O N Cy 1c Cy	
Entry	Deviation from the	e above conditions		1a (%)
1	Cy ₂ NH (2.5 equiv.)		19
2	Cy ₂ NH•HCl (2.5 equiv.)			46
3	Cy ₂ NH•HCl (2.0 equiv.)			59
4	Cy ₂ NH•HCl (1.5 equiv.)			65
5	$Cy_2NH \bullet HCl (1.0 equiv.)$			47
6 ^b	Cy ₂ NH•HC	l (1.5 equiv.)		71

Table S9. Optimization the reaction conditions for secondary amines.

Reaction conditions: (*E*)-prop-1-en-1-ylbenzene (0.2 mmol), Cu(OAc)₂ (5 mol%), DPPE (5 mol%), NaOEt (2.75 equiv.), B₂Pin₂ (3.5 equiv.), amines (x equiv.), DMSO (1 mL), CO (10 bar), 60 °C, 20 h; yields are determined by ¹H NMR spectra of the crude reaction mixture. [b] Cu(OAc)₂ (10 mol%), DPPE (10 mol%)


3. General procedure.

3.1 General procedure A for primary amines.



A dried vial (4 mL) was charged with Cu(OAc)₂ (5 mol%), DPPE (5 mol%), B₂pin₂ (3.5 equiv.), and a stirring bar. When the NaOEt (2.75 equiv.) is added, the vial was sealed by PTFE/white rubber septum (Wheaton 13 mm Septa) and phenolic cap immediately. The vial was evacuated under vacuum and recharged with argon for three times with a needle. Then, internal aryl olefins (0.2 mmol), aryl amines or alkyl amines (2.5 equiv.) and DMSO (1.0 mL) were added under argon by using a syringe. The vial (or several vials) was placed in an alloy plate and transferred into a 300 mL autoclave of the 4560 series from Parr Instruments. The autoclave was charged with CO (10 bar) after flushing two times with N₂ and two times with CO. The autoclave was then placed into an aluminum block on a magnetic stirrer. The reaction was performed for 20 h at 60 °C. After the reaction was complete, the autoclave was cooled down to room temperature and the pressure was released carefully. The reaction was quenched with water (2 mL) and extracted with EtOAc (2 mLx3). The organic layer was washed with water (10 mL) and dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. After that the corresponding products was afforded by directly purified by fast column chromatography. (For NMR yield: The organic layer was washed with water and 0.1 mmol of 1,3,5-trimethoxybenzene was added. After drying with anhydrous Na_2SO_4 , an appropriate amount of organic layer was concentrated under reduced pressure to test the NMR yield.)


3.2 General procedure B for secondary amines-hydrochloride.



A dried vial (4 mL) was charged with Cu(OAc)₂ (10 mol%), DPPE (10 mol%), B₂pin₂ (3.5 equiv.), and a stirring bar. When the NaOEt (2.75 equiv.) is added, the vial was sealed by PTFE/white rubber septum (Wheaton 13 mm Septa) and phenolic cap immediately. The vial was evacuated under vacuum and recharged with argon for three times with a needle. Then, internal aryl olefins (0.2 mmol), secondary amines hydrochloride (1.5 equiv.) and DMSO (1.0 mL) were added under argon by using a syringe. The vial (or several vials) was placed in an alloy plate and transferred into a 300 mL autoclave of the 4560 series from Parr Instruments. The autoclave was charged with CO (10 bar) after flushing two times with N₂ and two times with CO. The autoclave was then placed into an aluminum block on a magnetic stirrer. The reaction was performed for 20 h at 60 °C. After the reaction was complete, the autoclave was cooled down to room temperature and the pressure was released carefully. The reaction was quenched with water (2 mL) and extracted with EtOAc (2 mLx3). The organic layer was washed with water (10 mL) and dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. After that the corresponding products was afforded by directly purified by fast column chromatography. (For NMR yield: The organic layer was washed with water and 0.1 mmol of 1,3,5-trimethoxybenzene was added. After drying with anhydrous Na₂SO₄, an appropriate amount of organic layer was concentrated under reduced pressure to test the NMR yield.)

3.3 Failed examples.

Failed examples of amines



4. Characterization Data.

N,3-Diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (1a)


The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and aniline (2.5 equiv., 45 µL), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (41 mg, 54%).

¹H NMR (300 MHz, CDCl₃) δ 7.33 – 7.27 (m, 2H), 7.26 – 7.16 (m, 7H), 7.10 – 6.91 (m, 2H), 3.16 (td, *J* = 10.2, 4.1 Hz, 1H), 2.80 (dd, *J* = 14.0, 4.1 Hz, 1H), 2.62 (dd, *J* = 14.0, 10.3 Hz, 1H), 1.53 – 1.40 (m, 1H), 1.29 (d, *J* = 1.6 Hz, 12H), 0.81 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.0, 143.7, 137.8, 128.7, 128.6, 127.8, 126.6, 123.9, 119.7, 83.4, 45.7, 45.3, 24.9, 24.6, 14.0.

¹¹B NMR (96 MHz, CDCl₃) δ 33.4.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₃H₃₀¹¹BNO₃ 402.2215, found: 402.2221.



3-Phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(p-tolyl)pentanamide (2a)

The title compound was prepared from *trans-* β -methylstyrene (0.2 mmol, 26 µL) and *p*-toluidine (2.5 equiv., 54 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (31 mg, 40%).

¹H NMR (300 MHz, CDCl₃) δ 7.34 – 7.21 (m, 5H), 7.17 – 7.00 (m, 4H), 6.93 (s, 1H), 3.17 (td, J = 10.2, 4.1 Hz, 1H), 2.81 (dd, J = 14.0, 4.1 Hz, 1H), 2.62 (dd, J = 14.0, 10.3 Hz, 1H), 2.28 (s, 3H), 1.52 – 1.43 (m, 1H), 1.31 (d, J = 1.2 Hz, 12H), 0.83 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 169.9, 143.7, 135.2, 133.5, 129.2, 128.6, 127.9, 126.6, 119.8, 83.4, 45.8, 45.3, 24.9, 24.7, 20.8, 14.0.

¹¹B NMR (96 MHz, CDCl₃) δ 34.3

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₄H₃₂¹⁰BNO₃415.2404, found: 415.2404.

3-Phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(m-tolyl)pentanamide (3a)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and *m*-toluidine (2.5 equiv., 54 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (32 mg, 41%).

¹H NMR (300 MHz, CDCl₃) δ 7.34 – 7.27 (m, 2H), 7.25 – 7.20 (m, 3H), 7.14 (s, 1H), 7.10 (t, *J* = 7.8 Hz, 1H), 6.95 (d, *J* = 12.5 Hz, 2H), 6.84 (d, *J* = 7.4 Hz, 1H), 3.15 (td, *J* = 10.2, 4.1 Hz, 1H), 2.79 (dd, *J* = 14.0, 4.1 Hz, 1H), 2.60 (dd, *J* = 14.0, 10.3 Hz, 1H), 2.27 (s, 3H), 1.50 – 1.40 (m, 1H), 1.29 (d, *J* = 1.8 Hz, 12H), 0.81 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 169.9, 143.7, 138.7, 137.7, 128.6, 128.5, 127.9, 126.6, 124.7, 120.4, 116.7, 83.4, 45.7, 45.4, 24.9, 24.6, 21.4, 14.0.

¹¹B NMR (96 MHz, CDCl₃) δ 32.9.

HRMS (ESI-TOF): calcd for $[M+Na]^+ C_{24}H_{32}^{10}BNO_3415.2404$, found: 415.2406.

3-Phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(o-tolyl)pentanamide (4a)


The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and *o*-toluidine (2.5 equiv., 54 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (44 mg, 56%).

¹H NMR (300 MHz, CDCl₃) δ 7.56 (d, *J* = 8.0 Hz, 1H), 7.34 – 7.26 (m, 3H), 7.25 – 7.17 (m, 2H), 7.13 – 6.93 (m, 3H), 6.67 (s, 1H), 3.18 (td, *J* = 10.6, 3.9 Hz, 1H), 2.85 (dd, *J* = 14.1, 3.7 Hz, 1H), 2.73 – 2.62 (m, 1H), 1.82 (s, 3H), 1.42 (t, *J* = 8.5 Hz, 1H), 1.28 (d, *J* = 1.8 Hz, 12H), 0.80 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.0, 143.5, 135.6, 130.2, 129.0, 128.7, 128.0, 126.7, 126.5, 124.9, 123.1, 83.4, 45.7, 45.0, 24.9, 24.6, 17.3, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.8.

HRMS (ESI-TOF): calcd for $[M+Na]^+ C_{24}H_{32}^{10}BNO_3415.2404$, found: 415.2408.



3-Phenyl-N-(2-propylphenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (5a)


The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 2-propylaniline (2.5 equiv., 68 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (35 mg, 41%).

¹H NMR (300 MHz, CDCl₃) δ 7.59 (d, *J* = 7.8 Hz, 1H), 7.35 – 7.22 (m, 5H), 7.18 – 7.03 (m, 3H), 6.74 (s, 1H), 3.22 (td, *J* = 10.6, 3.7 Hz, 1H), 2.88 (dd, *J* = 14.0, 3.7 Hz, 1H), 2.73 – 2.59 (m, 1H), 2.16 (dq, *J* = 15.8, 7.6 Hz, 2H), 1.43 (q, *J* = 7.4 Hz, 3H), 1.32 – 1.27 (m, 12H), 0.92 – 0.81 (m, 6H).

¹³C NMR (75 MHz, CDCl₃) δ 170.1, 143.5, 135.0, 133.4, 129.2, 128.7, 127.9, 126.7, 126.4, 125.0, 123.8, 83.4, 45.6, 45.1, 32.8, 24.9, 24.6, 22.6, 13.9, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 34.2.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{26}H_{36}^{11}BNO_3 422.2866$, found: 422.2866.



N-(2-Ethoxyphenyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (6a)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 2-ethoxyaniline (2.5 equiv., 69 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (49 mg, 58%).

¹H NMR (300 MHz, CDCl₃) δ 8.24 (dd, J = 8.0, 1.4 Hz, 1H), 7.54 (s, 1H), 7.25 (d, J = 5.8 Hz, 4H), 7.18 – 7.11 (m, 1H), 6.89 (dtd, J = 24.2, 7.6, 1.6 Hz, 2H), 6.77 (dd, J = 8.0, 1.5 Hz, 1H), 4.00 (qd, J = 7.0, 4.1 Hz, 2H), 3.22 (td, J = 10.1, 4.4 Hz, 1H), 2.86 (dd, J = 14.3, 4.4 Hz, 1H), 2.66 (dd, J = 14.4, 10.4 Hz, 1H), 1.51 – 1.41 (m, 1H), 1.39 (t, J = 7.0 Hz, 3H), 1.26 (d, J = 2.0 Hz, 12H), 0.80 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 169.7, 146.9, 143.6, 137.0, 128.3, 127.9, 126.3, 123.2, 120.8, 119.8, 110.8, 83.3, 64.0, 45.2, 45.1, 25.0, 24.9, 24.6, 14.8, 13.8.

¹¹B NMR (96 MHz, CDCl₃) δ 30.1.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₅H₃₄¹⁰BNO₃ 445.2509, found: 445.2511.

N-(2-Fluorophenyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (7a)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 2-fluoroaniline (2.5 equiv., 55.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (46 mg, 59%).

¹H NMR (400 MHz, CDCl₃) δ 8.20 (t, *J* = 7.8 Hz, 1H), 7.35 (s, 1H), 7.32 – 7.28 (m, 2H), 7.26 – 7.18 (m, 3H), 7.11 – 6.95 (m, 3H), 3.20 (td, *J* = 10.1, 4.1 Hz, 1H), 2.88 (dd, *J* = 14.2, 4.1 Hz, 1H), 2.70 (dd, *J* = 14.2, 10.2 Hz, 1H), 1.51 – 1.43 (m, 1H), 1.30 (d, *J* = 2.3 Hz, 12H), 0.83 (d, *J* = 7.5 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 170.1, 152.1 (d, J = 243.0 Hz), 143.4, 128.5, 127.7, 126.5, 126.4 (d, J = 10.2 Hz), 124.3 (d, J = 3.6 Hz), 123.8 (d, J = 7.5 Hz), 121.6, 114.5 (d, J = 19.2 Hz), 83.4, 45.6, 45.2, 24.8, 24.6, 14.0.

¹¹B NMR (128 MHz, CDCl₃) δ 35.3.

 ^{19}F NMR (282 MHz, CDCl₃) δ -131.2.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₃H₂₉¹⁰BFNO₃ 397.2334, found: 397.2337.

N-(2-(Difluoromethoxy)phenyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (8a) The title compound was prepared from *trans-* β -methylstyrene (0.2 mmol, 26 µL) and 2-(difluoromethoxy)aniline (2.5 equiv., 32 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (20 mg, 22%).


¹H NMR (300 MHz, CDCl₃) δ 8.15 (d, J = 8.1 Hz, 1H), 7.28 (s, 1H), 7.22 – 7.16 (m, 3H), 7.15 – 6.99 (m, 3H), 6.96 – 6.88 (m, 2H), 6.24 (t, J = 73.6 Hz, 1H), 3.11 (td, J = 10.3, 4.2 Hz, 1H), 2.80 (dd, J = 14.2, 4.2 Hz, 1H), 2.60 (dd, J = 14.2, 10.5 Hz, 1H), 1.39 – 1.30 (m, 1H), 1.20 (d, J = 2.0 Hz, 12H), 0.73 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.1, 143.3, 139.9, 129.9, 128.5, 127.8, 126.5, 126.0, 123.8, 121.6, 118.4, 116.2 (d, *J* = 261.1 Hz), 83.3, 45.4, 45.1, 25.0, 24.8, 24.6, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.2.

¹⁹F NMR (282 MHz, CDCl₃) δ -79.75 (d, J = 6.4 Hz), -80.01 (d, J = 6.1 Hz).

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₄H₃₀¹¹BF₂NO₄ 468.2132, found: 468.2128.



3-Phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)*-N***-(4-(trifluoromethyl)phenyl)pentanamide (9a)**

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 4-(trifluoromethyl)aniline (2.5 equiv., 80.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (47 mg, 53%).


¹H NMR (300 MHz, CDCl₃) δ 7.34 – 7.27 (m, 2H), 7.26 – 7.12 (m, 5H), 7.06 (d, J = 8.2 Hz, 3H), 3.13 (td, J = 10.2, 4.0 Hz, 1H), 2.80 (dd, J = 14.0, 4.1 Hz, 1H), 2.61 (dd, J = 14.0, 10.3 Hz, 1H), 1.52 – 1.39 (m, 1H), 1.29 (d, J = 1.6 Hz, 12H), 0.81 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.1, 143.6, 136.4, 128.7, 127.8, 126.7, 121.5, 120.8, 120.4 (q, J = 257.4 Hz), 83.5, 45.8, 45.3, 24.9, 24.6, 14.0.

¹¹B NMR (96 MHz, CDCl₃) δ 33.4.

¹⁹F NMR (282 MHz, CDCl₃) δ -58.2.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₄H₂₉¹⁰BF₃NO₃ 447.2302, found: 447.2293.



3-Phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(4-(trifluoromethoxy)phenyl)pentanamide (10a)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 4-(trifluoromethoxy)aniline (2.5 equiv., 88.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 7:1, Rf = 0.2) to give the product as a white solid (28 mg, 30%).


¹H NMR (300 MHz, CDCl₃) δ 7.34 – 7.28 (m, 2H), 7.26 – 7.18 (m, 5H), 7.07 (d, J = 8.3 Hz, 2H), 7.00 (s, 1H), 3.13 (td, J = 10.3, 3.9 Hz, 1H), 2.80 (dd, J = 14.0, 4.0 Hz, 1H), 2.61 (dd, J = 13.9, 10.3 Hz, 1H), 1.50 – 1.41 (m, 1H), 1.29 (d, J = 1.5 Hz, 12H), 0.81 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.1, 143.6, 136.5, 128.8, 127.9, 126.8, 121.6, 120.8, 120.4 (q, *J* = 256.8 Hz), 83.5, 45.8, 45.4, 24.9, 24.7, 14.1.

¹¹B NMR (96 MHz, CDCl₃) δ 34.6.

¹⁹F NMR (282 MHz, CDCl₃) δ -58.2.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{24}H_{29}^{10}BF3NO_4463.2251$, found: 463.2252.



N-(4-Fluorophenyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (11a)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 4-fluoroaniline (2.5 equiv., 55.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (46 mg, 58%).


¹H NMR (300 MHz, CDCl₃) δ 7.34 – 7.27 (m, 2H), 7.24 – 7.18 (m, 3H), 7.19 – 7.10 (m, 2H), 7.02 – 6.83 (m, 3H), 3.14 (td, *J* = 10.3, 4.1 Hz, 1H), 2.79 (dd, *J* = 13.9, 4.1 Hz, 1H), 2.59 (dd, *J* = 13.9, 10.4 Hz, 1H), 1.50 – 1.40 (m, 1H), 1.28 (d, *J* = 1.4 Hz, 12H), 0.81 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.0, 159.2 (d, *J* = 243.6 Hz), 143.6, 133.7 (d, *J* = 2.3 Hz) 128.7, 127.8, 126.7, 121.6 (d, *J* = 7.8 Hz), 115.4 (d, *J* = 22.4 Hz), 83.4, 45.8, 45.2, 24.9, 24.7, 14.0.

¹¹B NMR (96 MHz, CDCl₃) δ 33.6.

¹⁹F NMR (282 MHz, CDCl₃) δ -118.48 (tt, *J* = 9.1, 5.1 Hz).

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₃H₂₉¹¹BFNO₃ 398.2302, found: 398.2306.



N-(4-Benzylphenyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (12a)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 4-benzylaniline (2.5 equiv., 91.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (50 mg, 49%).

¹H NMR (300 MHz, CDCl₃) δ 7.32 – 7.21 (m, 7H), 7.21 – 7.11 (m, 5H), 7.09 – 6.99 (m, 3H), 3.91 (s, 2H), 3.17 (td, J = 10.1, 4.1 Hz, 1H), 2.81 (dd, J = 14.0, 4.1 Hz, 1H), 2.62 (dd, J = 14.0, 10.3 Hz, 1H), 1.57 – 1.39 (m, 1H), 1.30 (d, J = 1.4 Hz, 12H), 0.83 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.0, 143.7, 141.1, 136.8, 135.9, 129.2, 128.9, 128.7, 128.4, 127.9, 126.7, 126.0, 120.0, 83.5, 45.8, 45.3, 41.3, 24.9, 24.6, 14.0.

¹¹B NMR (128 MHz, CDCl₃) δ 33.3.

HRMS (ESI-TOF): calcd for $[M+Na]^+ C_{30}H_{36}^{10}BNO_3 491.2717$, found: 491.2720.

N-(4-(Morpholinomethyl)phenyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (13a)


The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and 4-(morpholinomethyl)aniline (2.5 equiv., 96 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 1:1, Rf = 0.2) to give the product as a white solid (39 mg, 41%).

¹H NMR (300 MHz, CDCl₃) δ 7.37 – 7.27 (m, 2H), 7.26 – 7.04 (m, 7H), 7.00 (s, 1H), 3.79 – 3.66 (m, 4H), 3.45 (s, 2H), 3.14 (td, J = 10.2, 4.1 Hz, 1H), 2.79 (dd, J = 14.0, 4.0 Hz, 1H), 2.61 (d, J = 3.7 Hz, 1H), 2.51 – 2.33 (m, 4H), 1.45 (dd, J = 10.1, 7.5 Hz, 1H), 1.28 (d, J = 1.7 Hz, 12H), 0.80 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.0, 143.7, 129.9, 128.7, 128.7, 127.9, 126.7, 119.6, 83.4, 66.6, 62.7, 53.3, 45.7, 45.3, 24.9, 24.7, 14.0.

¹¹B NMR (96 MHz, CDCl₃) δ 35.1.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₈H₃₉¹⁰BN₂O₄478.3112, found: 478.3108.




N-(4-(Dimethylamino)phenyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (14a) The title compound was prepared from *trans-* β -methylstyrene (0.2 mmol, 26 µL) and N^{l} , N^{l} -dimethylbenzene-1,4-diamine (2.5 equiv., 68 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 1:1, Rf = 0.2) to give the product as a white solid (36 mg, 43%).

¹H NMR (300 MHz, CDCl₃) δ 7.32 – 7.16 (m, 5H), 7.09 (d, J = 8.7 Hz, 2H), 7.00 – 6.40 (m, 3H), 3.15 (td, J = 10.2, 4.1 Hz, 1H), 2.85 (dd, J = 38.5, 12.4 Hz, 6H), 2.73 (s, 1H), 2.58 (dd, J = 13.8, 10.4 Hz, 1H), 1.45 (dd, J = 9.5, 6.9 Hz, 1H), 1.28 (d, J = 1.5 Hz, 12H), 0.81 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 169.8, 143.8, 128.6, 127.9, 126.6, 121.6, 83.4, 45.8, 45.1, 41.7, 24.9, 24.7, 14.0. ¹¹B NMR (96 MHz, CDCl₃) δ 34.0.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₅H₃₅¹⁰BN₂O₃422.2850, found: 422.2847.




N-(2,4-Dimethylphenyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (15a)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 2,4-dimethylaniline (2.5 equiv., 60.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (36 mg, 44%).

¹H NMR (300 MHz, CDCl₃) δ 7.34 (s, 1H), 7.23 – 7.10 (m, 5H), 6.85 (d, *J* = 7.6 Hz, 1H), 6.72 (d, *J* = 7.2 Hz, 1H), 6.56 (s, 1H), 3.11 (td, *J* = 10.6, 3.9 Hz, 1H), 2.77 (dd, *J* = 13.8, 3.9 Hz, 1H), 2.59 (dd, *J* = 13.9, 11.0 Hz, 1H), 2.17 (s, 3H), 1.70 (s, 3H), 1.25 (d, *J* = 7.8 Hz, 1H), 1.21 (d, *J* = 2.2 Hz, 12H), 0.73 (d, *J* = 7.4 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 170.0, 155.7, 143.6, 136.2, 135.4, 129.9, 128.7, 128.0, 126.7, 125.8, 125.6, 123.6, 83.4, 45.7, 45.1, 24.9, 24.6, 21.0, 16.8, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 34.1.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₅H₃₄¹⁰BNO₃ 407.2741, found: 407.2741.



N-(Benzo[d][1,3] dioxol-5-yl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) pentanamide (16a)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and benzo[*d*][1,3]dioxol-5amine (2.5 equiv., 68.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 6:1, Rf = 0.2) to give the product as a white solid (49 mg, 58%).

¹H NMR (300 MHz, CDCl₃) δ 7.34 – 7.27 (m, 2H), 7.22 (d, *J* = 6.9 Hz, 3H), 6.92 (d, *J* = 2.1 Hz, 1H), 6.87 (s, 1H), 6.63 (d, *J* = 8.3 Hz, 1H), 6.44 (dd, *J* = 8.3, 2.1 Hz, 1H), 5.88 (s, 2H), 3.13 (td, *J* = 10.3, 4.1 Hz, 1H), 2.77 (dd, *J* = 13.9, 4.1 Hz, 1H), 2.56 (dd, *J* = 13.9, 10.4 Hz, 1H), 1.52 – 1.42 (m, 1H), 1.29 – 1.27 (m, 12H), 0.80 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 169.9, 147.5, 144.0, 143.7, 132.0, 128.6, 127.8, 126.7, 113.0, 107.8, 102.9, 101.1, 83.4, 45.8, 45.2, 24.9, 24.7, 14.0.
¹¹B NMR (96 MHz, CDCl₃) δ 34.6.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{24}H_{30}^{11}BNO_5 424.2294$, found: 424.2294.

Bpin

N-(2,2-Difluorobenzo[d][1,3] dioxol-5-yl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-dioxaborola

yl)pentanamide (17a)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and 2,2-difluorobenzo[*d*][1,3]dioxol-5-amine (2.5 equiv., 86.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 7:1, Rf = 0.2) to give the product as a white solid (36 mg, 40%).


¹H NMR (400 MHz, CDCl₃) δ 7.38 – 7.27 (m, 3H), 7.22 (td, J = 6.4, 1.7 Hz, 3H), 6.98 (s, 1H), 6.85 (d, J = 8.6 Hz, 1H), 6.59 (dd, J = 8.6, 2.1 Hz, 1H), 3.12 (td, J = 10.3, 4.0 Hz, 1H), 2.79 (dd, J = 13.9, 4.0 Hz, 1H), 2.59 (dd, J = 13.9, 10.4 Hz, 1H), 1.45 (dd, J = 10.2, 7.4 Hz, 1H), 1.29 (d, J = 2.3 Hz, 12H), 0.81 (d, J = 7.4 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 170.1, 143.7, 143.5, 139.9, 133.9, 131.7 (t, *J* = 231.5 Hz), 128.7, 127.8, 126.8, 114.4, 109.0, 103.1, 83.5, 45.9, 45.3, 24.9, 24.7, 14.0.

¹¹B NMR (128 MHz, CDCl₃) δ 35.4.

¹⁹F NMR (282 MHz, CDCl₃) δ -50.0.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₄H₂₈¹⁰BF₂NO₅ 481.1957, found: 481.1956.



N-(3-Fluoro-4-morpholinophenyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (18a)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 3-fluoro-4morpholinoaniline (2.5 equiv., 98 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.3) to give the product as a white solid (58 mg, 60%).


¹H NMR (300 MHz, CDCl₃) δ 7.31 – 7.26 (m, 2H), 7.25 – 7.11 (m, 4H), 7.02 (s, 1H), 6.88 – 6.62 (m, 2H), 3.89 – 3.80 (m, 4H), 3.13 (dt, *J* = 10.2, 5.1 Hz, 1H), 3.05 – 2.92 (m, 4H), 2.77 (dd, *J* = 14.0, 4.1 Hz, 1H), 2.58 (dd, *J* = 14.0, 10.3 Hz, 1H), 1.56 – 1.37 (m, 1H), 1.27 (d, *J* = 1.7 Hz, 12H), 0.80 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.0, 155.3 (d, J = 245.7 Hz), 143.6, 135.7 (d, J = 16.6 Hz), 133.3 (d, J = 12.6 Hz), 128.6, 127.8, 126.7, 118.7 (d, J = 3.6 Hz), 115.5 (d, J = 3.3 Hz), 108.9 (d, J = 25.4 Hz), 83.4, 66.8, 51.1, 45.7, 45.2, 24.9, 24.6, 14.0.

¹¹B NMR (96 MHz, CDCl₃) δ 33.9.

¹⁹F NMR (282 MHz, CDCl₃) δ -121.2.

HRMS (ESI-TOF): calcd for $[M+Na]^+ C_{27}H_{36}^{10}BFN_2O_4 504.2680$, found: 504.2679.



N-(1-Methyl-1*H*-indol-5-yl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (19a)


The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 1-methyl-1*H*-indol-5amine (2.5 equiv., 73 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 3:1, Rf = 0.2) to give the product as a white solid (42 mg, 49%).

¹H NMR (300 MHz, CDCl₃) δ 7.54 (d, J = 1.9 Hz, 1H), 7.34 – 7.22 (m, 5H), 7.13 (d, J = 8.7 Hz, 1H), 7.01 – 6.90 (m, 3H), 6.37 (dd, J = 3.1, 0.7 Hz, 1H), 3.71 (s, 3H), 3.21 (td, J = 10.2, 4.2 Hz, 1H), 2.83 (dd, J = 13.9, 4.2 Hz, 1H), 2.62 (dd, J = 13.9, 10.4 Hz, 1H), 1.52 – 1.43 (m, 1H), 1.30 (d, J = 1.3 Hz, 12H), 0.84 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 169.9, 143.9, 134.0, 130.1, 129.4, 128.5, 128.3, 127.9, 126.5, 115.8, 112.6, 109.0, 100.9, 83.3, 45.8, 45.2, 32.8, 24.9, 24.6, 14.0.

¹¹B NMR (96 MHz, CDCl₃) δ 32.9.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{26}H_{33}^{11}BN_2O_3433.2662$, found: 433.2670.



N-(Benzofuran-5-yl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (20a)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and benzo[*d*][1,3]dioxol-5amine (2.5 equiv., 68.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 6:1, Rf = 0.2) to give the product as a white solid (51 mg, 61%).

¹H NMR (300 MHz, CDCl₃) δ 7.66 (d, J = 2.0 Hz, 1H), 7.55 (d, J = 2.2 Hz, 1H), 7.34 – 7.27 (m, 3H), 7.26 – 7.20 (m, 3H), 7.10 (s, 1H), 6.89 (dd, J = 8.8, 2.1 Hz, 1H), 6.66 (dd, J = 2.1, 0.8 Hz, 1H), 3.18 (td, J = 10.2, 4.2 Hz, 1H), 2.83 (dd, J = 13.9, 4.2 Hz, 1H), 2.63 (dd, J = 13.9, 10.3 Hz, 1H), 1.50 – 1.42 (m, 1H), 1.30 – 1.27 (m, 12H), 0.82 (d, J = 7.5 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.1, 151.8, 145.6, 143.7, 132.9, 128.6, 127.9, 127.6, 126.6, 117.5, 113.0, 111.1, 106.7, 83.4, 45.8, 45.1, 24.9, 24.7, 14.0.

¹¹B NMR (96 MHz, CDCl₃) δ 33.0.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₅H₃₀¹¹BNO₃ 420.2345, found: 420.2343.

N-Pentyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (1b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and pentan-1-amine (2.5 equiv., 39 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (33 mg, 44%).

¹H NMR (300 MHz, CDCl₃) δ 7.31 – 7.26 (m, 1H), 7.24 (d, J = 2.0 Hz, 1H), 7.20 – 7.13 (m, 3H), 5.12 (s, 1H), 3.12 – 2.89 (m, 3H), 2.64 (dd, J = 13.9, 4.2 Hz, 1H), 2.39 (dd, J = 13.9, 11.0 Hz, 1H), 1.41 – 1.33 (m, 1H), 1.26

(d, *J* = 2.0 Hz, 12H), 1.17 (ddd, *J* = 9.4, 6.3, 2.6 Hz, 4H), 1.01 (ddd, *J* = 12.6, 7.5, 2.3 Hz, 2H), 0.84 – 0.73 (m, 6H).

¹³C NMR (75 MHz, CDCl₃) δ 171.6, 143.7, 128.4, 127.8, 126.4, 83.3, 45.6, 44.1, 39.2, 36.3, 29.0, 28.8, 24.8, 24.6, 22.2, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 34.2.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₂H₃₆¹⁰BNO₃ 395.2717, found: 395.2721.

Bpin.

N-Hexadecyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (2b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and hexadecan-1-amine (2.5 equiv., 120 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (60 mg, 57%).

¹H NMR (300 MHz, CDCl₃) δ 7.29 – 7.24 (m, 2H), 7.21 – 7.14 (m, 3H), 5.44 (s, 1H), 3.09 – 2.97 (m, 3H), 2.66 (dd, J = 14.0, 4.6 Hz, 1H), 2.44 (dd, J = 14.0, 10.6 Hz, 1H), 1.34 (d, J = 7.5 Hz, 1H), 1.29 – 1.18 (m, 40H), 0.90 – 0.85 (m, 3H), 0.77 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 172.0, 143.7, 128.4, 127.8, 126.4, 83.3, 45.5, 43.6, 39.5, 31.9, 29.7, 29.7, 29.6, 29.6, 29.5, 29.3, 29.2, 26.7, 24.8, 24.7, 22.8, 22.7, 14.5, 14.1, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 32.8.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₃₃H₅₈¹⁰BNO₃ 527.4619, found: 527.4622.

N-(2-Ethylhexyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (3b)


The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 2-ethylhexan-1-amine (2.5 equiv., 129 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (49 mg, 59%).

¹H NMR (400 MHz, CDCl₃) δ 7.28 – 7.24 (m, 2H), 7.20 – 7.12 (m, 3H), 5.07 (s, 1H), 3.06 (td, *J* = 10.5, 3.8 Hz, 1H), 3.02 – 2.84 (m, 2H), 2.64 (dd, *J* = 14.0, 4.0 Hz, 1H), 2.44 (dd, *J* = 14.0, 11.1 Hz, 1H), 1.36 – 1.31 (m, 1H), 1.25 (d, *J* = 3.3 Hz, 12H), 1.19 (dd, *J* = 8.1, 5.7 Hz, 2H), 1.14 – 1.06 (m, 3H), 1.02 – 0.89 (m, 4H), 0.85 (t, *J* = 7.2 Hz, 3H), 0.76 (d, *J* = 7.4 Hz, 3H), 0.71 (td, *J* = 7.4, 2.1 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 171.7, 143.7, 128.5, 127.9, 126.5, 83.3, 45.5, 44.1, 41.9, 39.1, 30.7, 28.8, 24.9, 24.7, 23.9, 22.9, 14.1, 13.9, 10.8.

¹¹B NMR (128 MHz, CDCl₃) δ 33.3.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{25}H_{42}^{10}BNO_3 415.3367$, found: 415.3372.



N-(Cycloheptylmethyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (4b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and cycloheptylmethanamine (2.5 equiv., 63.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (48 mg, 58%).

¹H NMR (300 MHz, CDCl₃) δ 7.28 – 7.23 (m, 2H), 7.20 – 7.11 (m, 3H), 5.31 (s, 1H), 3.06 (td, *J* = 10.6, 4.1 Hz, 1H), 2.91 (dt, *J* = 12.8, 6.3 Hz, 1H), 2.79 (dt, *J* = 13.1, 5.9 Hz, 1H), 2.65 (dd, *J* = 14.0, 4.1 Hz, 1H), 2.43 (dd, *J* = 13.9, 11.1 Hz, 2H), 1.60 – 1.41 (m, 5H), 1.35 (ddt, *J* = 19.0, 6.3, 2.8 Hz, 6H), 1.26 – 1.24 (m, 12H), 0.92 – 0.82 (m, 2H), 0.76 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.8, 143.6, 128.4, 127.9, 126.4, 83.3, 45.9, 45.5, 44.0, 39.3, 31.9, 31.8, 28.2, 28.1, 26.3, 26.2, 24.9, 24.7, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.1.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{25}H_{40}^{10}BNO_3 413.3210$, found: 413.3210.

Bpin

3-Phenyl-N-(3-phenylpropyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (5b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 3-phenylpropan-1-amine (2.5 equiv., 67.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (55 mg, 65%).

¹H NMR (300 MHz, CDCl₃) δ 7.29 – 7.22 (m, 4H), 7.21 – 7.12 (m, 4H), 7.10 – 6.96 (m, 2H), 5.13 (t, *J* = 5.1 Hz, 1H), 3.21 – 2.89 (m, 3H), 2.64 (dd, *J* = 13.9, 4.1 Hz, 1H), 2.54 – 2.19 (m, 3H), 1.51 (p, *J* = 7.2 Hz, 2H), 1.40 – 1.36 (m, 1H), 1.26 (d, *J* = 2.2 Hz, 12H), 0.77 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.6, 143.7, 141.4, 128.4, 128.3, 127.9, 126.4, 125.8, 83.2, 45.5, 44.1, 38.7, 32.8, 30.9, 24.8, 24.6, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.0.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{26}H_{36}^{11}BNO_3 422.2866$, found: 422.2870.

N-Phenethyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (6b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 2-phenylethan-1-amine (2.5 equiv., 60.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (42 mg, 52%).

¹H NMR (300 MHz, CDCl₃) δ 7.29 – 7.19 (m, 5H), 7.16 (ddd, J = 7.8, 4.2, 1.7 Hz, 3H), 7.06 – 6.84 (m, 2H), 5.24 (s, 1H), 3.37 (dq, J = 13.5, 6.4 Hz, 1H), 3.28 – 2.96 (m, 2H), 2.63 (dd, J = 13.9, 4.2 Hz, 1H), 2.58 – 2.30 (m, 3H), 1.38 – 1.32 (m, 1H), 1.25 (d, J = 2.2 Hz, 12H), 0.76 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.7, 143.7, 138.9, 128.6, 128.5, 128.4, 127.9, 126.4, 126.3, 83.2, 45.4, 44.0, 40.4, 35.5, 24.8, 24.6, 13.8.

¹¹B NMR (96 MHz, CDCl₃) δ 33.3.

HRMS (ESI-TOF): calcd for $[M+Na]^+ C_{25}H_{34}^{11}BNO_3 430.2528$, found: 430.2529.

N-(4-Methoxyphenethyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (7b)


The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 2-(4-methoxyphenyl)ethan-1-amine (2.5 equiv., 75.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 4:1, Rf = 0.2) to give the product as a white solid (48 mg, 55%).

¹H NMR (300 MHz, CDCl₃) δ 7.31 – 7.25 (m, 2H), 7.23 – 7.15 (m, 3H), 6.92 – 6.85 (m, 2H), 6.83 – 6.74 (m, 2H), 5.29 (s, 1H), 3.80 (s, 3H), 3.35 (dq, *J* = 13.4, 6.4 Hz, 1H), 3.23 – 3.05 (m, 2H), 2.64 (dd, *J* = 13.9, 4.2 Hz, 1H), 2.54 – 2.35 (m, 3H), 1.40 – 1.32 (m, 1H), 1.27 (d, *J* = 2.3 Hz, 12H), 0.78 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.6, 158.1, 143.7, 130.9, 129.5, 128.3, 127.8, 126.3, 113.8, 83.2, 55.2, 45.3, 43.9, 40.5, 34.5, 24.8, 24.6, 13.8.

¹¹B NMR (96 MHz, CDCl₃) δ 32.7.

HRMS (ESI-TOF): calcd for $[M+Na]^+ C_{26}H_{36}^{11}BNO_4 460.2634$, found: 460.2635.



N-(4-Fluorophenethyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (8b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 2-(4-fluorophenyl)ethan-1amine (2.5 equiv., 69.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (36 mg, 42%).

¹H NMR (300 MHz, CDCl₃) δ 7.30 – 7.23 (m, 2H), 7.21 – 7.13 (m, 3H), 6.97 – 6.85 (m, 4H), 5.34 (s, 1H), 3.35 (dq, *J* = 13.4, 6.4 Hz, 1H), 3.22 – 3.02 (m, 2H), 2.66 – 2.30 (m, 4H), 1.34 (d, *J* = 4.1 Hz, 1H), 1.25 (d, *J* = 2.2 Hz, 12H), 0.75 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.9, 161.5 (d, *J* = 244.4 Hz), 143.7, 134.5 (d, *J* = 3.4 Hz), 130.1 (d, *J* = 7.8 Hz), 128.4, 127.9, 126.5, 115.27 (d, *J* = 21.1 Hz), 83.3, 45.4, 43.8, 40.6, 34.7, 24.9, 24.7, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 32.8.

¹⁹F NMR (282 MHz, CDCl₃) δ -116.89 (p, *J* = 7.0 Hz).

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₅H₃₃¹¹BFNO₃ 448.2434, found: 448.2434.

Ph^{uu}O Ph^{uu}O H

3-Phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-*N*-(3-(trifluoromethyl)phenethyl)pentanamide (9b)


The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and 2-(3-(trifluoromethyl)phenyl)ethan-1-amine (2.5 equiv., 94.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (44 mg, 46%).

¹H NMR (300 MHz, CDCl₃) δ 7.45 (d, *J* = 7.8 Hz, 1H), 7.35 (t, *J* = 7.7 Hz, 1H), 7.30 – 7.22 (m, 3H), 7.20 – 7.10 (m, 4H), 5.36 (s, 1H), 3.36 (dt, *J* = 13.7, 6.9 Hz, 1H), 3.20 (td, *J* = 13.0, 7.2 Hz, 1H), 3.05 (td, *J* = 10.5, 4.2 Hz, 1H), 2.66 – 2.57 (m, 2H), 2.49 (dt, *J* = 14.1, 7.4 Hz, 1H), 2.38 (dd, *J* = 14.0, 10.8 Hz, 1H), 1.35 – 1.32 (m, 1H), 1.25 (d, *J* = 1.9 Hz, 12H), 0.76 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.9, 143.6, 139.9, 132.1, 130.8 (q, J = 31.5 Hz), 128.9, 128.4, 127.8, 126.4, 125.3 (q, J = 3.7 Hz), 123.2 (q, J = 3.7 Hz), 119.8 (q, J = 251.0 Hz), 83.3, 45.5, 43.8, 40.2, 35.3, 24.8, 24.6, 13.9. ¹¹B NMR (96 MHz, CDCl₃) δ 32.9.

¹⁹F NMR (282 MHz, CDCl₃) δ -62.5.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₆H₃₃¹¹BF₃NO₃ 498.2402, found: 498.2405.



N-(3-Methoxypropyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (10b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 3-methoxypropan-1-amine (2.5 equiv., 44.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 1:1, Rf = 0.2) to give the product as a white solid (40 mg, 53%).

¹H NMR (300 MHz, CDCl₃) δ 7.23 – 7.16 (m, 2H), 7.15 – 7.02 (m, 3H), 5.48 (s, 1H), 3.17 (s, 3H), 3.15 – 2.94 (m, 5H), 2.57 (dd, J = 13.8, 4.3 Hz, 1H), 2.31 (dd, J = 13.6, 10.7 Hz, 1H), 1.43 – 1.25 (m, 3H), 1.19 (d, J = 2.7 Hz, 12H), 0.70 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.5, 143.7, 128.3, 127.8, 126.3, 83.2, 70.9, 58.5, 45.4, 43.9, 37.2, 28.9, 24.8, 24.6, 24.5, 13.8.

¹¹B NMR (96 MHz, CDCl₃) δ 33.5.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₁H₃₄¹¹BNO₄ 398.2477, found: 398.2478.

Ph^u O N H

N-(3-((tert-Butyldimethylsilyl) oxy) propyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-dioxabor

yl)pentanamide (11b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and 3-((*tert*-butyldimethylsilyl)oxy)propan-1-amine (2.5 equiv., 94.5 mg), according to general procedure. The crude residue


was purified by flash chromatography (*n*-pentane/EA = 4:1, Rf = 0.2) to give the product as a white solid (52 mg, 54%).

¹H NMR (300 MHz, CDCl₃) δ 7.24 (d, J = 2.3 Hz, 2H), 7.20 – 7.14 (m, 3H), 5.59 (s, 1H), 3.53 – 3.38 (m, 2H), 3.18 – 3.01 (m, 3H), 2.64 (dd, J = 13.8, 4.4 Hz, 1H), 2.34 (dd, J = 13.8, 10.8 Hz, 1H), 1.48 – 1.33 (m, 3H), 1.26 (d, J = 1.9 Hz, 12H), 0.88 (s, 9H), 0.78 (d, J = 7.4 Hz, 3H), 0.02 (s, 6H).

¹³C NMR (75 MHz, CDCl₃) δ 171.4, 143.8, 128.3, 127.9, 126.2, 83.2, 61.6, 45.4, 44.0, 37.3, 31.6, 25.9, 24.8, 24.6, 18.2, 13.9, -5.4.

¹¹B NMR (96 MHz, CDCl₃) δ 33.7.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₆H₄₆¹¹BNO₄Si 476.3367, found: 476.3370.



N-(2-(Cyclohex-1-en-1-yl)ethyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (12b) The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and 2-(cyclohex-1-en-1-yl)ethan-1-amine (2.5 equiv., 62.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (52 mg, 63%).

¹H NMR (300 MHz, CDCl₃) δ 7.29 – 7.24 (m, 2H), 7.16 (ddd, J = 8.2, 4.8, 1.7 Hz, 3H), 5.39 – 4.86 (m, 2H), 3.07 (dq, J = 10.0, 5.3 Hz, 3H), 2.64 (dd, J = 13.9, 4.4 Hz, 1H), 2.39 (dd, J = 13.9, 10.7 Hz, 1H), 1.93 (d, J = 1.8 Hz, 2H), 1.88 – 1.67 (m, 4H), 1.52 (tdd, J = 7.8, 6.2, 3.3 Hz, 4H), 1.40 – 1.33 (m, 1H), 1.25 (d, J = 2.2 Hz, 12H), 0.76 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.6, 143.7, 134.5, 128.3, 127.8, 126.4, 123.1, 83.2, 45.4, 43.9, 37.2, 36.9, 27.7, 25.1, 24.8, 24.7, 22.7, 22.3, 13.8.

¹¹B NMR (96 MHz, CDCl₃) δ 33.3.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₅H₃₈¹¹BNO₃ 434.2841, found: 434.2838.

Bpin Ph


N-(But-3-en-1-yl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (13b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and but-3-en-1-amine (2.5 equiv., 30.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (44 mg, 61%).

¹H NMR (300 MHz, CDCl₃) δ 7.29 – 7.24 (m, 2H), 7.17 (ddq, *J* = 6.8, 3.1, 1.8 Hz, 3H), 5.52 (ddt, *J* = 17.1, 10.3, 6.8 Hz, 1H), 5.30 (s, 1H), 5.01 – 4.77 (m, 2H), 3.17 – 3.00 (m, 3H), 2.65 (dd, *J* = 13.9, 4.4 Hz, 1H), 2.40 (dd, *J* = 13.9, 10.7 Hz, 1H), 2.05 – 1.85 (m, 2H), 1.39 – 1.32 (m, 1H), 1.26 (d, *J* = 1.9 Hz, 12H), 0.77 (d, *J* = 7.4 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 171.8, 143.7, 135.1, 128.4, 127.9, 126.4, 116.9, 83.3, 45.5, 43.8, 38.3, 33.4, 24.8, 24.6, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.3.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₁H₃₂¹⁰BNO₃ 357.2585, found: 357.2593.



N-Benzyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (14b)


The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and phenylmethanamine (2.5 equiv., 53.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (30 mg, 38%).

¹H NMR (300 MHz, CDCl₃) δ 7.22 – 7.14 (m, 3H), 7.11 (ddt, *J* = 4.4, 2.2, 1.1 Hz, 5H), 6.93 – 6.57 (m, 2H), 5.42 (d, *J* = 5.1 Hz, 1H), 4.24 (dd, *J* = 14.9, 6.2 Hz, 1H), 4.08 – 4.00 (m, 1H), 3.06 (td, *J* = 10.8, 4.1 Hz, 1H), 2.65 (dd, *J* = 13.8, 4.1 Hz, 1H), 2.37 (dd, *J* = 13.9, 11.1 Hz, 1H), 1.32 – 1.26 (m, 1H), 1.18 (d, *J* = 1.7 Hz, 12H), 0.71 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.5, 143.6, 138.1, 128.4, 128.4, 127.9, 127.4, 127.1, 126.4, 83.2, 45.5, 44.0, 43.2, 24.8, 24.6, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.2.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₄H₃₂¹⁰BNO₃ 393.2585, found: 393.2588.



N-Isopropyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (15b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and propan-2-amine (2.5 equiv., 29.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (38 mg, 55%).

¹H NMR (300 MHz, CDCl₃) δ 7.30 – 7.26 (m, 1H), 7.24 (s, 1H), 7.21 – 7.14 (m, 3H), 5.04 (d, J = 7.0 Hz, 1H), 3.92 – 3.71 (m, 1H), 3.04 (td, J = 10.6, 4.4 Hz, 1H), 2.62 (dd, J = 13.6, 4.4 Hz, 1H), 2.36 – 2.32 (m, 1H), 1.42 – 1.33 (m, 1H), 1.27 (d, J = 1.3 Hz, 12H), 0.92 (d, J = 6.6 Hz, 3H), 0.80 – 0.73 (m, 6H).

¹³C NMR (75 MHz, CDCl₃) δ 171.0, 143.7, 128.4, 127.9, 126.4, 83.3, 45.8, 44.2, 41.0, 24.8, 24.6, 22.4, 22.3, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.6.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₀H₃₂¹¹BNO₃ 346.2552, found: 346.2555.

Bpin

N-(Heptan-2-yl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (16b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and heptan-2-amine (2.5 equiv., 57.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (51 mg, 64%).

¹H NMR (300 MHz, CDCl₃) δ 7.23 – 7.17 (m, 2H), 7.14 – 7.08 (m, 3H), 4.94 (d, J = 8.8 Hz, 1H), 3.72 – 3.57 (m, 1H), 2.97 (td, J = 10.8, 4.2 Hz, 1H), 2.58 (dd, J = 13.8, 4.2 Hz, 1H), 2.32 (dd, J = 13.8, 11.1 Hz, 1H), 1.37 – 1.27 (m, 1H), 1.20 (d, J = 1.6 Hz, 12H), 1.16 – 0.96 (m, 8H), 0.77 (t, J = 7.0 Hz, 3H), 0.71 (d, J = 7.4 Hz, 3H), 0.65 (d, J = 6.6 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.1, 143.6, 128.4, 127.9, 126.4, 83.3, 45.7, 44.9, 44.1, 36.6, 31.6, 25.4, 24.8, 24.7, 22.5, 20.5, 14.0, 13.9.

 ^{11}B NMR (96 MHz, CDCl₃) δ 33.1.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{24}H_{40}^{10}BNO_3 401.3210$, found: 401.3219.

Bpin,


N-Cyclopropyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (17b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and cyclopropanamine (2.5 equiv., 28.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (28 mg, 41%).

¹H NMR (300 MHz, CDCl₃) δ 7.28 – 7.26 (m, 1H), 7.23 (q, J = 1.4 Hz, 1H), 7.20 – 7.12 (m, 3H), 5.21 (s, 1H), 3.03 (td, J = 10.6, 4.2 Hz, 1H), 2.60 (dd, J = 13.7, 4.3 Hz, 1H), 2.43 (tq, J = 7.0, 3.8 Hz, 1H), 2.31 (dd, J = 13.7, 11.0 Hz, 1H), 1.47 – 1.34 (m, 1H), 1.25 (d, J = 1.6 Hz, 12H), 0.76 (d, J = 7.4 Hz, 3H), 0.62 – 0.49 (m, 2H), 0.19 – -0.09 (m, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 173.1, 143.7, 128.3, 127.8, 126.4, 83.3, 45.7, 44.0, 24.8, 24.6, 22.1, 13.9, 6.5, 6.3. ¹¹B NMR (96 MHz, CDCl₃) δ 33.3.

HRMS (ESI-TOF): calcd for $[M+Na]^+ C_{20}H_{30}^{10}BNO_3 365.2247$, found: 365.2255.



N-Cyclobutyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (18b)


The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and cyclobutanamine (2.5 equiv., 35.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (35 mg, 49%).

¹H NMR (300 MHz, CDCl₃) δ 7.28 (dt, *J* = 7.2, 1.2 Hz, 1H), 7.25 (d, *J* = 0.7 Hz, 1H), 7.21 – 7.09 (m, 3H), 5.23 (d, *J* = 6.9 Hz, 1H), 4.15 (h, *J* = 7.9 Hz, 1H), 3.03 (td, *J* = 10.5, 4.2 Hz, 1H), 2.59 (dd, *J* = 13.7, 4.3 Hz, 1H), 2.33 (dd, *J* = 13.7, 10.8 Hz, 1H), 2.09 (dddd, *J* = 17.3, 6.2, 4.6, 2.8 Hz, 2H), 1.53 (dt, *J* = 5.0, 3.2 Hz, 2H), 1.46 – 1.28 (m, 3H), 1.26 (d, *J* = 1.6 Hz, 12H), 0.77 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.8, 143.8, 128.4, 127.9, 126.4, 83.3, 45.7, 44.3, 44.1, 31.0, 30.8, 24.8, 24.6, 14.9, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.2.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{21}H_{32}^{10}BNO_3 357.2585$, found: 357.2585.



N-Cyclopentyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (19b)


The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and cyclopentanamine (2.5 equiv., 42.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (34 mg, 47%).

¹H NMR (300 MHz, CDCl₃) δ 7.28 (dt, *J* = 7.0, 1.1 Hz, 1H), 7.26 – 7.21 (m, 1H), 7.21 – 7.12 (m, 3H), 5.05 (d, *J* = 7.0 Hz, 1H), 3.97 (h, *J* = 7.1 Hz, 1H), 3.03 (td, *J* = 10.7, 4.2 Hz, 1H), 2.61 (dd, *J* = 13.7, 4.2 Hz, 1H), 2.35 (dd, *J* = 13.7, 11.0 Hz, 1H), 1.80 – 1.59 (m, 2H), 1.41 (dtdd, *J* = 11.9, 8.2, 4.1, 2.2 Hz, 5H), 1.26 (d, *J* = 1.6 Hz, 12H), 1.06 (dd, *J* = 13.3, 7.2 Hz, 1H), 0.92 – 0.85 (m, 1H), 0.77 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.2, 143.7, 128.4, 127.9, 126.4, 83.3, 50.7, 45.8, 44.2, 32.8, 32.7, 24.8, 24.6, 23.5, 23.4, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.5.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{22}H_{34}^{10}BNO_3 371.2741$, found: 371.2750.



N-Cyclohexyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (20b)


The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and cyclohexanamine (2.5 equiv., 50.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (42 mg, 55%).

¹H NMR (300 MHz, CDCl₃) δ 7.29 – 7.23 (m, 2H), 7.19 – 7.13 (m, 3H), 4.99 (d, *J* = 8.1 Hz, 1H), 3.64 – 3.45 (m, 1H), 3.03 (td, *J* = 10.7, 4.2 Hz, 1H), 2.60 (dd, *J* = 13.7, 4.2 Hz, 1H), 2.34 (dd, *J* = 13.7, 11.0 Hz, 1H), 1.71 – 1.61 (m, 1H), 1.48 (dtt, *J* = 9.6, 7.3, 3.5 Hz, 4H), 1.26 (d, *J* = 1.8 Hz, 12H), 1.18 – 0.81 (m, 4H), 0.77 (d, *J* = 7.4 Hz, 3H), 0.72 – 0.60 (m, 1H).

¹³C NMR (75 MHz, CDCl₃) δ 170.6, 143.7, 128.3, 127.9, 126.3, 83.2, 47.5, 45.7, 44.3, 32.8, 32.7, 25.4, 24.8, 24.6, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 34.4.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₃H₃₆¹¹BNO₃ 386.2865, found: 386.2870.



N-((1*r*,4*r*)-4-Methoxycyclohexyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (21b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and (1*r*,4*r*)-4methoxycyclohexan-1-amine (2.5 equiv., 64.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 2:1, Rf = 0.2) to give the product as a white solid (31 mg, 37%). ¹H NMR (400 MHz, CDCl₃) δ 7.28 – 7.24 (m, 2H), 7.17 (td, J = 6.7, 1.4 Hz, 3H), 4.94 (d, J = 8.1 Hz, 1H), 3.53 (dtt, J = 15.1, 8.0, 4.0 Hz, 1H), 3.27 (s, 3H), 3.08 – 2.95 (m, 2H), 2.61 (dd, J = 13.7, 4.1 Hz, 1H), 2.34 (dd, J = 13.7, 11.1 Hz, 1H), 1.91 – 1.73 (m, 3H), 1.59 – 1.51 (m, 1H), 1.35 (ddd, J = 12.1, 7.4, 3.7 Hz, 1H), 1.26 (d, J = 2.9 Hz, 12H), 1.21 – 1.07 (m, 2H), 0.94 – 0.86 (m, 1H), 0.77 (d, J = 7.4 Hz, 3H), 0.74 – 0.64 (m, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 171.0, 143.6, 128.4, 127.9, 126.4, 83.3, 78.1, 55.7, 47.2, 45.8, 44.3, 30.3, 30.1, 29.9, 29.8, 24.8, 24.6, 13.9.

¹¹B NMR (128 MHz, CDCl₃) δ 35.7.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₄H₃₈¹¹BNO₄ 438.2790, found: 438.2794.

Bpin.

3-Phenyl-*N***-(tetrahydro-2***H***-pyran-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (22b)** The title compound was prepared from *trans-* β -methylstyrene (0.2 mmol, 26 µL) and tetrahydro-2*H*-pyran-4amine (2.5 equiv., 50.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 1:1, Rf = 0.3) to give the product as a white solid (40 mg, 52%).

¹H NMR (300 MHz, CDCl₃) δ 7.42 – 7.00 (m, 5H), 5.06 (d, *J* = 8.0 Hz, 1H), 3.74 (ddq, *J* = 16.9, 11.2, 3.5 Hz, 3H), 3.32 (tdd, *J* = 11.8, 9.5, 2.4 Hz, 2H), 3.03 (td, *J* = 10.7, 4.1 Hz, 1H), 2.63 (dd, *J* = 13.6, 4.2 Hz, 1H), 2.36 (dd, *J* = 13.6, 11.1 Hz, 1H), 1.64 (ddq, *J* = 11.6, 4.6, 2.5 Hz, 1H), 1.40 (dddd, *J* = 21.0, 10.8, 5.2, 2.8 Hz, 2H), 1.26 (d, *J* = 1.8 Hz, 12H), 1.20 – 1.10 (m, 1H), 1.04 – 0.93 (m, 1H), 0.77 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.0, 143.5, 128.4, 127.9, 126.5, 83.3, 66.5, 45.8, 45.0, 44.2, 32.7, 32.6, 24.8, 24.6, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.5.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₂H₃₄¹⁰BNO₄ 387.2690, found: 387.2693.


N-(tert-Butyl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (23b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and 2-methylpropan-2-amine (2.5 equiv., 36.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.3) to give the product as a white solid (36 mg, 50%).

¹H NMR (300 MHz, CDCl₃) δ 7.24 – 7.18 (m, 2H), 7.15 – 7.07 (m, 3H), 4.77 (s, 1H), 2.94 (td, *J* = 10.9, 4.1 Hz, 1H), 2.49 (dd, *J* = 13.4, 4.1 Hz, 1H), 2.21 (dd, *J* = 13.4, 11.3 Hz, 1H), 1.33 – 1.24 (m, 1H), 1.20 (s, 12H), 0.97 (s, 9H), 0.70 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.1, 143.8, 128.3, 128.0, 126.3, 83.2, 50.6, 46.1, 45.3, 28.4, 24.8, 24.6, 13.9. ¹¹B NMR (96 MHz, CDCl₃) δ 33.7.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{21}H_{34}^{11}BNO_3 360.2708$, found: 360.2709.



Ethyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanoyl)glycinate (24b)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 µL) and ethyl glycinate hydrogen chloride (1.5 equiv., 41.7 mg), according to general procedure B. The crude residue was purified by flash chromatography (*n*-pentane/EA = 4:1, Rf = 0.3) to give the product as a white solid (29 mg, 37%).

¹H NMR (300 MHz, CDCl₃) δ 7.28 – 7.24 (m, 2H), 7.22 – 7.13 (m, 3H), 5.75 (s, 1H), 4.14 (q, *J* = 7.1 Hz, 2H),

3.97 – 3.67 (m, 2H), 3.12 (td, *J* = 10.2, 4.2 Hz, 1H), 2.71 (dd, *J* = 14.2, 4.2 Hz, 1H), 2.52 (dd, *J* = 14.2, 10.5 Hz,

1H), 1.42 – 1.33 (m, 1H), 1.26 (d, J = 2.3 Hz, 12H), 1.24 (t, J = 2.1 Hz, 3H), 0.78 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.7, 169.9, 143.7, 128.3, 127.8, 126.4, 83.3, 61.3, 45.2, 43.4, 41.3, 24.9, 24.6,

14.1, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.9.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₁H₃₂¹¹BNO₅ 390.2450, found: 390.2451.

N,N-Dicyclohexyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (1c)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and dicyclohexylamine hydrochloride (1.5 equiv., 65 mg), according to general procedure B. The crude residue was purified by flash chromatography (*n*-pentane/EA = 7:1, Rf = 0.3) to give the product as a white solid (55 mg, 59%).

¹H NMR (300 MHz, CDCl₃) δ 7.28 – 7.15 (m, 5H), 3.39 (t, *J* = 10.5 Hz, 1H), 3.15 (td, *J* = 9.8, 5.4 Hz, 1H), 2.80 – 2.46 (m, 3H), 2.31 – 2.24 (m, 1H), 1.90 – 1.30 (m, 12H), 1.28 (s, 12H), 1.22 – 1.00 (m, 8H), 0.79 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.1, 144.0, 128.2, 128.0, 125.9, 82.9, 58.0, 56.0, 45.6, 41.3, 31.5, 30.9, 29.9, 29.8, 26.6, 26.6, 25.9, 25.2, 24.9, 24.7, 14.1.

¹¹B NMR (96 MHz, CDCl₃) δ 32.5.

3-Phenyl-N,N-dipropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (2c)

The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and dipropylamine hydrochloride (1.5 equiv., 41 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 7:1, Rf = 0.3) to give the product as a white solid (45 mg, 58%).

¹H NMR (300 MHz, CDCl₃) δ 7.31 – 7.20 (m, 1H), 7.18 – 7.11 (m, 4H), 3.28 – 3.05 (m, 2H), 2.94 (qt, *J* = 14.9, 8.5 Hz, 3H), 2.74 – 2.48 (m, 2H), 1.44 – 1.21 (m, 5H), 1.20 (s, 12H), 0.78 (t, *J* = 7.4 Hz, 3H), 0.69 (dd, *J* = 13.2, 7.4 Hz, 6H).

¹³C NMR (75 MHz, CDCl₃) δ 171.7, 144.3, 128.1, 128.1, 126.1, 83.0, 49.7, 47.8, 45.1, 39.2, 24.9, 24.8, 22.1, 20.7, 14.1, 11.2.

¹¹B NMR (96 MHz, CDCl₃) δ 31.4.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{23}H_{38}^{11}BNO_3 388.3022$, found: 388.3028.

N,*N*-Diisobutyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (3c)


The title compound was prepared from *trans-\beta*-methylstyrene (0.2 mmol, 26 μ L) and diisobutylamine hydrochloride (1.5 equiv., 49.5 mg), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 7:1, Rf = 0.3) to give the product as a white solid (51 mg, 61%).

¹H NMR (300 MHz, CDCl₃) δ 7.24 – 7.16 (m, 4H), 7.11 (ddd, *J* = 8.5, 5.3, 2.1 Hz, 1H), 3.39 – 3.14 (m, 2H), 3.04 (dd, *J* = 14.6, 7.3 Hz, 1H), 2.87 – 2.68 (m, 3H), 2.58 (dd, *J* = 14.6, 4.6 Hz, 1H), 1.76 (dhept, *J* = 27.5, 6.9 Hz, 2H), 1.36 (d, *J* = 3.7 Hz, 1H), 1.24 (s, 12H), 0.84 (dd, *J* = 6.7, 1.7 Hz, 6H), 0.77 (d, *J* = 7.4 Hz, 3H), 0.60 (dd, *J* = 6.7, 1.4 Hz, 6H).

¹³C NMR (75 MHz, CDCl₃) δ 172.0, 144.3, 128.0, 128.0, 125.9, 82.9, 55.8, 53.5, 45.2, 39.3, 28.0, 26.4, 24.9, 24.7, 20.0, 19.9, 14.1.

¹¹B NMR (96 MHz, CDCl₃) δ 32.6.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{25}H_{42}^{11}BNO_3 416.3335$, found: 416.3335.



N-Phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(p-tolyl)pentanamide (1d)


The title compound was prepared from (*E*)-1-methyl-4-(prop-1-en-1-yl)benzene (0.2 mmol, 26.4 mg) and aniline (2.5 equiv., 45 μ L), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (37 mg, 47%).

¹H NMR (400 MHz, CDCl₃) δ 7.27 – 7.20 (m, 4H), 7.11 (s, 5H), 7.05 – 7.00 (m, 1H), 3.11 (td, *J* = 10.2, 4.1 Hz, 1H), 2.77 (dd, *J* = 14.1, 4.1 Hz, 1H), 2.61 (dd, *J* = 14.1, 10.2 Hz, 1H), 2.31 (s, 3H), 1.46 – 1.39 (m, 1H), 1.29 (d, *J* = 2.3 Hz, 12H), 0.80 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 170.2, 140.5, 137.9, 136.1, 129.3, 128.7, 127.7, 123.9, 119.7, 83.4, 45.3, 45.3, 24.9, 24.6, 21.0, 14.0.

¹¹B NMR (128 MHz, CDCl₃) δ 33.4.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_{24}H_{32}^{11}BNO_3 394.2552$, found: 394.2560.



3-(4-Isobutylphenyl)-N-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (2d)


The title compound was prepared from (*E*)-1-isobutyl-4-(prop-1-en-1-yl)benzene (0.2 mmol, 34.8 mg) and aniline (2.5 equiv., 45 μ L), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (51 mg, 58%).

¹H NMR (400 MHz, CDCl₃) δ 7.20 (d, J = 4.3 Hz, 4H), 7.14 (d, J = 8.0 Hz, 2H), 7.08 (d, J = 8.1 Hz, 2H), 7.01 (d, J = 8.4, 4.1 Hz, 2H), 3.12 (dd, J = 10.2, 4.1 Hz, 1H), 2.78 (dd, J = 14.0, 4.1 Hz, 1H), 2.62 (dd, J = 14.0, 10.4 Hz, 1H), 2.43 (d, J = 7.2 Hz, 2H), 1.83 (dq, J = 13.5, 6.8 Hz, 1H), 1.43 (dt, J = 9.9, 7.5 Hz, 1H), 1.28 (d, J = 3.0 Hz, 12H), 0.87 (d, J = 1.6 Hz, 3H), 0.86 (d, J = 1.6 Hz, 3H), 0.81 (d, J = 7.4 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 170.2, 140.8, 140.0, 137.8, 129.4, 128.7, 127.6, 123.9, 119.7, 83.4, 45.3, 45.3, 45.0, 30.2, 24.9, 24.6, 22.3, 22.3, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 30.2.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₇H₃₈¹⁰BNO₃ 457.2873, found: 457.2878.



3-([1,1'-Biphenyl]-4-yl)-N-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (3d)


The title compound was prepared from (*E*)-4-(prop-1-en-1-yl)-1,1'-biphenyl (0.2 mmol, 38.8 mg) and aniline (2.5 equiv., 45 μ L), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (46 mg, 51%).

¹H NMR (300 MHz, CDCl₃) δ 7.56 (ddd, J = 10.8, 7.7, 1.6 Hz, 4H), 7.46 – 7.39 (m, 2H), 7.32 (tt, J = 8.2, 1.7 Hz, 3H), 7.27 – 7.16 (m, 4H), 7.13 – 6.96 (m, 2H), 3.22 (td, J = 10.1, 4.1 Hz, 1H), 2.84 (dd, J = 14.0, 4.1 Hz, 1H), 2.65 (dd, J = 14.0, 10.2 Hz, 1H), 1.50 (dd, J = 9.9, 7.5 Hz, 1H), 1.30 (d, J = 1.4 Hz, 12H), 0.87 (d, J = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.0, 142.8, 140.9, 139.4, 137.8, 128.8, 128.7, 128.3, 127.3, 127.1, 127.0, 123.9, 119.7, 83.4, 45.4, 45.3, 24.9, 24.7, 14.1.

¹¹B NMR (96 MHz, CDCl₃) δ 33.7.

HRMS (ESI-TOF): calcd for $[M+H]^+ C_9 H_{34}{}^{11}BNO_3 456.2710$, found: 456.2711.



3-(4-Fluorophenyl)-N-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (4d)

The title compound was prepared from (*E*)-1-fluoro-4-(prop-1-en-1-yl)benzene (0.2 mmol, 27.2 mg) and aniline (2.5 equiv., 45 μ L), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (34 mg, 43%).


¹H NMR (300 MHz, CDCl₃) δ 7.31 – 7.15 (m, 6H), 7.15 – 7.01 (m, 2H), 7.00 – 6.90 (m, 2H), 3.17 (td, *J* = 10.1, 4.2 Hz, 1H), 2.79 (dd, *J* = 14.0, 4.2 Hz, 1H), 2.55 (dd, *J* = 14.0, 10.1 Hz, 1H), 1.42 (dd, *J* = 10.3, 7.2 Hz, 1H), 1.28 (d, *J* = 1.1 Hz, 12H), 0.80 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 169.8, 161.5 (d, *J* = 244.4 Hz), 139.3 (d, *J* = 3.2 Hz), 137.7, 129.21 (d, *J* = 7.8 Hz), 128.9, 124.1, 119.7, 115.3 (d, *J* = 21.1 Hz), 83.5, 45.2, 44.9, 24.9, 24.7, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.8.

 ^{19}F NMR (282 MHz, CDCl_3) δ -116.5.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₃H₂₉¹¹BFNO₃ 420.2121, found: 420.2124.



3-(4-Methoxyphenyl)-N-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (5d)


The title compound was prepared from (*E*)-1-methoxy-4-(prop-1-en-1-yl)benzene (0.2 mmol, 29.6 mg) and aniline (2.5 equiv., 45 μ L), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.3) to give the product as a white solid (28 mg, 34%).

¹H NMR (300 MHz, CDCl₃) δ 7.28 – 7.19 (m, 4H), 7.15 (d, *J* = 8.6 Hz, 2H), 7.02 (t, *J* = 6.6 Hz, 2H), 6.88 – 6.75 (m, 2H), 3.77 (s, 3H), 3.10 (td, *J* = 10.2, 4.0 Hz, 1H), 2.77 (dd, *J* = 14.0, 4.0 Hz, 1H), 2.58 (dd, *J* = 14.0, 10.3 Hz, 1H), 1.44 – 1.36 (m, 1H), 1.28 (d, *J* = 1.5 Hz, 12H), 0.80 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.1, 158.2, 137.9, 135.6, 128.8, 123.9, 119.7, 114.0, 83.4, 55.2, 45.5, 44.9, 24.9, 24.7, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.9.

HRMS (ESI-TOF): calcd for $[M+Na]^+ C_{24}H_{32}^{10}BNO_4 431.2353$, found: 431.2363.



N-Phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(4-((((15,2R,4R)-1,7,7-

trimethylbicyclo[2.2.1]heptan-2-yl)oxy)methyl)phenyl)pentanamide (6d)


The title compound was prepared from (1S,2R,4R)-1,7,7-trimethyl-2-((4-((*E*)-prop-1-en-1-yl)benzyl)oxy)bicyclo[2.2.1]heptane (0.2 mmol, 56 mg) and aniline (2.5 equiv., 45 µL), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 5:1, Rf = 0.2) to give the product as a white solid (47 mg, 43%).

¹H NMR (300 MHz, CDCl₃) δ 7.29 – 7.18 (m, 8H), 7.07 – 6.95 (m, 2H), 4.55 – 4.38 (m, 2H), 3.67 (ddd, J = 9.4, 3.3, 1.8 Hz, 1H), 3.15 (td, J = 10.1, 4.0 Hz, 1H), 2.79 (dd, J = 14.0, 4.0 Hz, 1H), 2.61 (dd, J = 14.0, 10.2 Hz, 1H), 2.14 – 2.03 (m, 2H), 1.67 (ddd, J = 22.0, 8.5, 4.5 Hz, 3H), 1.49 – 1.42 (m, 1H), 1.29 – 1.28 (m, 12H), 1.07 (dd, J = 12.8, 3.1 Hz, 2H), 0.88 – 0.80 (m, 12H).

¹³C NMR (75 MHz, CDCl₃) δ 170.0, 142.6, 137.9, 137.9, 128.8, 127.7, 127.5, 123.9, 119.7, 84.4, 83.4, 71.4, 49.3, 47.8, 45.5, 45.0, 36.1, 31.5, 30.1, 29.7, 28.2, 26.7, 24.9, 24.7, 19.8, 18.9, 14.0.

¹¹B NMR (96 MHz, CDCl₃) δ 32.8.

HRMS (ESI-TOF): calcd for $[M+Na]^+ C_{34}H_{48}^{11}BNO_4 568.3574$, found: 568.3581.



N-Phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(o-tolyl)pentanamide (7d)


The title compound was prepared from (*E*)-1-methyl-2-(prop-1-en-1-yl)benzene (0.2 mmol, 26.4 mg) and aniline (2.5 equiv., 45 μ L), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (51 mg, 65%).

¹H NMR (300 MHz, CDCl₃) δ 7.26 – 7.18 (m, 6H), 7.11 (dd, *J* = 5.5, 1.9 Hz, 2H), 7.01 (ddd, *J* = 8.6, 5.9, 2.7 Hz, 1H), 6.89 (s, 1H), 3.48 (td, *J* = 10.4, 3.9 Hz, 1H), 2.80 (dd, *J* = 13.7, 3.9 Hz, 1H), 2.59 (dd, *J* = 13.7, 10.3 Hz, 1H), 2.33 (s, 3H), 1.48 – 1.40 (m, 1H), 1.30 (s, 12H), 0.81 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.2, 142.6, 137.9, 137.2, 130.5, 128.8, 126.5, 126.1, 125.3, 123.8, 119.6, 83.4, 45.4, 40.1, 24.9, 24.6, 20.1, 14.0.

¹¹B NMR (96 MHz, CDCl₃) δ 33.9.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₄H₃₂¹¹BNO₃ 394.2552, found: 394.2556.



3-(3,4-Difluorophenyl)-N-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (8d)

The title compound was prepared from (*E*)-1,2-difluoro-4-(prop-1-en-1-yl)benzene (0.2 mmol, 30 mg) and aniline (2.5 equiv., 45 μ L), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (39 mg, 47%).


¹H NMR (300 MHz, CDCl₃) δ 7.36 – 7.23 (m, 5H), 7.05 (qd, *J* = 8.3, 3.6 Hz, 3H), 6.94 (d, *J* = 2.0 Hz, 1H), 3.19 (td, *J* = 9.8, 4.3 Hz, 1H), 2.80 (dd, *J* = 14.2, 4.3 Hz, 1H), 2.53 (dd, *J* = 14.2, 9.9 Hz, 1H), 1.42 – 1.34 (m, 1H), 1.28 (s, 12H), 0.81 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 169.5, 148.9 (d, *J* = 259.2 Hz), 145.9, 140.9 (t, *J* = 4.3 Hz), 139.3 (d, *J* = 242.7 Hz), 128.9, 124.2, 123.9, (dd, *J* = 6.1, 3.3 Hz), 119.8, 117.0 (d, *J* = 16.5 Hz), 116.3 (d, *J* = 16.9 Hz), 83.6, 44.8, 44.6, 24.9, 24.7, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.2.

¹⁹F NMR (282 MHz, CDCl₃) δ -136.48 - -138.67 (m), -139.95 - -141.22 (m).

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₃H₂₈¹⁰BF₂NO₃ 437.2059, found: 437.2069.



3-(Naphthalen-2-yl)-N-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanamide (9d)

The title compound was prepared from (*E*)-2-(prop-1-en-1-yl)naphthalene (0.2 mmol, 33.6 mg) and aniline (2.5 equiv., 45 μ L), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (45 mg, 53%).

¹H NMR (300 MHz, CDCl₃) δ 7.83 – 7.73 (m, 3H), 7.68 (s, 1H), 7.47 – 7.36 (m, 3H), 7.25 – 7.10 (m, 4H), 7.07 (s, 1H), 6.99 (dq, *J* = 8.6, 4.2 Hz, 1H), 3.35 (td, *J* = 9.9, 4.2 Hz, 1H), 2.88 (dd, *J* = 14.2, 4.2 Hz, 1H), 2.73 (dd, *J* = 14.1, 9.9 Hz, 1H), 1.60 – 1.51 (m, 1H), 1.30 (d, *J* = 2.0 Hz, 12H), 0.83 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.0, 141.2, 137.8, 133.5, 132.4, 128.7, 128.4, 127.7, 127.6, 126.9, 126.0, 125.6, 125.4, 123.9, 119.7, 83.5, 45.8, 45.2, 24.9, 24.7, 14.1.

¹¹B NMR (96 MHz, CDCl₃) δ 33.6.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₇H₃₂¹⁰BNO₃ 451.2404, found: 451.2409.

N,3-Diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanamide (10d)

The title compound was prepared from (*E*)-but-1-en-1-ylbenzene (0.2 mmol, 26.4 mg) and aniline (2.5 equiv., 45 μ L), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (33 mg, 42%).

¹H NMR (300 MHz, CDCl₃) δ 7.34 – 7.27 (m, 2H), 7.25 – 7.15 (m, 7H), 7.01 (dt, *J* = 12.5, 6.2 Hz, 2H), 3.22 (td, *J* = 10.3, 3.9 Hz, 1H), 2.77 (dd, *J* = 13.9, 3.9 Hz, 1H), 2.58 (dd, *J* = 13.9, 10.5 Hz, 1H), 1.54 – 1.35 (m, 1H), 1.32 (s, 12H), 1.23 (d, *J* = 6.3 Hz, 2H), 0.83 (t, *J* = 7.3 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.0, 144.1, 137.8, 128.8, 128.7, 127.8, 126.7, 124.0, 119.8, 83.5, 45.6, 44.5, 25.0, 24.9, 22.7, 13.4.

¹¹B NMR (96 MHz, CDCl₃) δ 33.3.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₄H₃₂¹⁰BNO₃ 393.2585, found: 393.2596.

N,3-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)heptanamide (11d)

The title compound was prepared from (*E*)-pent-1-en-1-ylbenzene (0.2 mmol, 29.2 mg) and aniline (2.5 equiv., 45 μ L), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (43 mg, 53%).

¹H NMR (300 MHz, CDCl₃) δ 7.33 – 7.27 (m, 2H), 7.25 – 7.16 (m, 7H), 7.01 (dt, *J* = 12.0, 5.9 Hz, 2H), 3.20 (td, *J* = 10.3, 3.9 Hz, 1H), 2.76 (dd, *J* = 13.9, 3.9 Hz, 1H), 2.59 (dd, *J* = 13.9, 10.5 Hz, 1H), 1.49 – 1.39 (m, 1H), 1.31 (s, 12H), 1.23 (d, *J* = 2.8 Hz, 2H), 1.14 (ddd, *J* = 17.6, 8.4, 3.6 Hz, 2H), 0.77 (t, *J* = 6.9 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 169.9, 144.1, 137.8, 128.7, 128.7, 127.7, 126.6, 123.9, 119.7, 83.4, 45.5, 44.7, 32.0, 25.0, 24.8, 22.1, 14.3.

¹¹B NMR (96 MHz, CDCl₃) δ 33.0.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₅H₃₄¹⁰BNO₃ 429.2560, found: 429.2566.

`Ń____Ph

5-Methyl-N,3-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanamide (12d)

The title compound was prepared from (*E*)-(3-methylbut-1-en-1-yl)benzene (0.2 mmol, 29.2 mg) and aniline (2.5 equiv., 45 μ L), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (42 mg, 51%).

¹H NMR (300 MHz, CDCl₃) δ 7.35 – 7.26 (m, 2H), 7.26 – 7.16 (m, 7H), 7.07 – 6.95 (m, 1H), 6.86 (s, 1H), 3.33 (td, J = 10.9, 3.5 Hz, 1H), 2.72 (dd, J = 13.7, 3.5 Hz, 1H), 2.51 (dd, J = 13.7, 10.7 Hz, 1H), 1.50 – 1.37 (m, 2H), 1.33 (d, J = 2.9 Hz, 12H), 0.88 (dd, J = 15.8, 6.8 Hz, 6H).

¹³C NMR (75 MHz, CDCl₃) δ 169.9, 143.9, 137.8, 128.8, 128.7, 127.7, 126.6, 123.9, 119.7, 83.5, 46.2, 43.0,

27.2, 25.3, 25.0, 23.4, 19.1.

¹¹B NMR (96 MHz, CDCl₃) δ 33.7.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₅H₃₄¹¹BNO₃ 430.2528, found: 430.2533.

4-Cyclohexyl-N,3-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butanamide (13d)

The title compound was prepared from (*E*)-(2-cyclohexylvinyl)benzene (0.2 mmol, 37.2 mg) and aniline (2.5 equiv., 45 μ L), according to general procedure. The crude residue was purified by flash chromatography (*n*-pentane/EA = 10:1, Rf = 0.2) to give the product as a white solid (43 mg, 48%).

¹H NMR (300 MHz, CDCl₃) δ 7.32 – 7.26 (m, 2H), 7.26 – 7.10 (m, 7H), 7.01 (dt, J = 8.6, 4.2 Hz, 1H), 6.94 (s,

1H), 3.39 (td, *J* = 10.8, 3.6 Hz, 1H), 2.71 (dd, *J* = 13.8, 3.6 Hz, 1H), 2.53 (dd, *J* = 13.8, 10.7 Hz, 1H), 1.64 – 1.51 (m, 4H), 1.33 (d, *J* = 4.5 Hz, 12H), 1.17 – 0.80 (m, 8H).


¹³C NMR (75 MHz, CDCl₃) δ 170.0, 144.0, 137.8, 128.7, 128.7, 127.6, 126.5, 123.9, 119.7, 83.5, 45.8, 42.0, 37.3, 33.8, 30.3, 26.7, 26.7, 26.4, 25.2, 25.0.

¹¹B NMR (96 MHz, CDCl₃) δ 31.0.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₂₈H₃₈¹¹BNO₃ 448.3023, found: 448.3025.

5. Derivatization of 1a.

5.1 Oxidation of 1a.




The title compound **1e** was synthesized according to the following literature¹: A 25 mL flask charged with **1a** (0.1 mmol) and THF/H₂O (1.0 mL/0.5 mL). Then the NaBO₃•4H₂O (5 equiv.) was added to a solution. The resulting mixture was stirred vigorously for 3 h at room temperature, then quenched with water and extracted with ethyl acetate (5 mL). The combined organic layers were washed with brine (15 mL), dried over Na₂SO₄ and concentrated. Purification by column chromatography on silica gel gave the corresponding product **1e** as a colorless oil (98% yield).

4-Hydroxy-N,3-diphenylpentanamide (1e)

¹H NMR (300 MHz, CDCl₃) δ 7.39 – 7.34 (m, 2H), 7.32 – 7.24 (m, 5H), 7.23 – 7.19 (m, 2H), 7.09 (td, *J* = 6.2, 2.8 Hz, 1H), 4.01 (s, 1H), 3.12 (dt, *J* = 8.4, 6.3 Hz, 1H), 2.98 (dd, *J* = 14.6, 5.9 Hz, 1H), 2.75 (dd, *J* = 14.6, 6.6 Hz, 1H), 2.64 (d, *J* = 5.7 Hz, 1H), 1.10 (d, *J* = 6.2 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 171.4, 142.3, 137.7, 128.8, 128.7, 127.9, 126.9, 124.3, 120.2, 71.7, 50.8, 41.4, 22.1.

5.2 Vinylation of **1a**.



The title compound **2e** was synthesized according to the modified following literature²: an oven-dried round bottom flask was charged with a stirring bar, **1a** (0.1 mmol) in THF (1 mL). VinyImagnesium bromide (1 M, 0.4 mL, 4.0 equiv.) was added dropwise to the mixture at room temperature. The resulting mixture was stirred for 0.5 h and then cooled to -78 °C. A solution of I₂ (4.0 equiv.) in methanol (1.0 mL) was added dropwise and the mixture was allowed to stir 0.5 h at the same temperature. A solution of NaOMe (8.0 equiv.) in methanol (1.5 mL) was added dropwise. Then the reaction mixture was warmed to room temperature and stirred for another 1.5 h. The reaction mixture was quenched by saturated Na₂S₂O₃ (2 mL) and diluted with EtOAc (10 mL) and water 10 mL. The combined organic layer was dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel to afford the corresponding product **2e** as a colorless oil (93%).


4-Methyl-N,3-diphenylhex-5-enamide (2e)

¹H NMR (300 MHz, CDCl₃) δ 7.36 – 7.28 (m, 2H), 7.27 – 7.10 (m, 7H), 7.06 – 6.90 (m, 1H), 6.79 (s, 1H), 5.75 (ddd, *J* = 17.1, 10.1, 8.9 Hz, 1H), 5.19 – 4.98 (m, 2H), 2.99 (td, *J* = 9.9, 4.3 Hz, 1H), 2.89 (dd, *J* = 14.3, 4.3 Hz, 1H), 2.57 – 2.32 (m, 2H), 0.84 (d, *J* = 6.7 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 170.2, 142.8, 142.7, 137.6, 128.8, 128.7, 128.1, 126.8, 124.1, 119.9, 115.1, 48.1, 44.3, 43.5, 19.1.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₁₉H₂₁NO 302.1515, found: 302.1518.

5.3 Preparation of trifluoroboration salt of 1a.




The title compound **3e** was prepared according to the following literature⁴: an oven-dried 25 mL Schlenk tube was charged with **1a** (0.1 mmol) and MeCN (0.2 mL). The reaction mixture was stirred vigorously for 1 h at room temperature after KHF₂ (4.0 equiv.) was added. The resulting slurry was stirred concentrated, then placed under high vacuum for 1 h. The dried solids were triturated with hot acetone and filtered to remove inorganic salts. The combined organic layers were concentrated and Et₂O (5 mL) was added, then the mixture was sonicated for 15 minutes, and the organic layer was removed, and this step was repeated. The trifluoroboration salt **4e** was obtained as a white solid (82% yield).

N,3-Diphenyl-4-(trifluoro- λ 4-boraneyl)pentanamide, potassium salt (3e)

¹H NMR (300 MHz, DMSO) δ 9.38 (s, 1H), 7.38 (d, *J* = 7.6 Hz, 2H), 7.22 – 7.05 (m, 6H), 6.98 (tt, *J* = 6.3, 2.9 Hz, 1H), 6.90 (t, *J* = 7.3 Hz, 1H), 3.09 (dd, *J* = 14.9, 3.9 Hz, 1H), 2.85 (td, *J* = 10.9, 3.7 Hz, 1H), 2.50 – 2.42 (m, 1H), 0.40 (s, 3H).

¹³C NMR (75 MHz, DMSO) δ 171.7, 148.0, 139.5, 128.3, 128.2, 127.2, 124.5, 122.4, 118.9, 45.8, 43.4, 15.9. ¹¹B NMR (96 MHz, DMSO) δ 6.6.

5.4 *N*-Arylation of **1a**.



The title compound **4e** was prepared according to the following literature³: an oven-dried 25 mL Schlenk tube was charged with **1a** (0.1 mmol), CuBr₂ (10 mol%), and Cs₂CO₃ (2.0 equiv.). The tube was evacuated under vacuum and recharged with argon for three times. Then 1-iodo-3-methylbenzene (2.0 equiv.), 1,2-dimethylethylenediamine (DMEDA, 20 mol%), and toluene (1 mL) was injected into the tube. The resulted mixture was allowed to stir at 130 °C for 24 h. Then the reaction mixture was cooled to room temperature. Then the solution was extracted by EtOAc (5 mLx2) and dried over Na₂SO₄. The combined organic layer was concentrated under reduced pressure and purified by column chromatography to give the corresponding **3e** in 61% yield.

N,3-Diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(m-tolyl)pentanamide (4e)

¹H NMR (300 MHz, CDCl₃) δ 7.29 – 7.09 (m, 6H), 7.11 – 6.95 (m, 4H), 6.80 (d, *J* = 7.3 Hz, 2H), 6.55 (s, 2H), 3.20 (dt, *J* = 9.9, 7.6 Hz, 1H), 2.56 (d, *J* = 8.0 Hz, 2H), 2.19 (s, 3H), 1.19 (d, *J* = 6.1 Hz, 1H), 1.14 (s, 12H), 0.67 (d, *J* = 7.4 Hz, 3H).


¹³C NMR (75 MHz, CDCl₃) δ 172.0, 144.0, 143.0, 142.8, 129.0, 128.9, 128.8, 128.7, 128.7, 128.6, 128.4, 128.0, 126.1, 83.0, 45.8, 41.1, 24.8, 24.6, 21.2, 14.1.

¹¹B NMR (96 MHz, CDCl₃) δ 33.3.

HRMS (ESI-TOF): calcd for [M+H]⁺ C₃₀H₃₆¹¹BNO₃ 470.2867, found: 470.2872.

6. Mechanism studies.

6.1 ¹³C labeling experiment.



A dried vial (4 mL) was charged with Cu(OAc)₂ (5 mol%), DPPE (5 mol%), B₂pin₂ (3.5 equiv.), and a stirring bar. When the NaOEt (2.75 equiv.) is added, the vial was sealed by PTFE/white rubber septum (Wheaton 13 mm Septa) and phenolic cap immediately. The vial was evacuated under vacuum and recharged with argon for three


times with a needle. Then, *trans-β*-methylstyrene (0.2 mmol), aniline (2.5 equiv.) and DMSO (1.0 mL) were added under argon by using a syringe. The vial (or several vials) was placed in an alloy plate and transferred into a 300 mL autoclave of the 4560 series from Parr Instruments. The autoclave was charged with ¹³CO (5 bar) and CO (5 bar) after flushing two times with N₂ and two times with CO. The autoclave was then placed into an aluminum block on a magnetic stirrer. The reaction was performed for 20 h at 60 °C. After the reaction was complete, the autoclave was cooled down to room temperature and the pressure was released carefully. The reaction was quenched with water (2 mL) and extracted with EtOAc (2 mLx3). The organic layer was washed with water (10 mL) and dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. After that the corresponding products **1a**-¹³C was afforded as a white solid in 80% NMR yield and 58% isolated yield by directly purified by fast column chromatography. (For NMR yield: The organic layer was washed with water and 0.1 mmol of 1,3,5-trimethoxybenzene was added. After drying with anhydrous Na₂SO₄, an appropriate amount of organic layer was concentrated under reduced pressure to test the NMR yield.)

¹H NMR (300 MHz, CDCl₃) δ 7.32 – 7.16 (m, 10H), 7.05 – 6.94 (m, 1H), 3.18 (ddd, *J* = 10.0, 6.0, 2.0 Hz, 1H), 3.07 – 2.72 (m, 1H), 2.68 – 2.33 (m, 1H), 1.46 (dd, *J* = 15.5, 7.3 Hz, 1H), 1.27 (d, *J* = 2.1 Hz, 12H), 0.81 (d, *J* = 7.4 Hz, 3H).


¹³C NMR (75 MHz, CDCl₃) δ 170.0 (d, J = 51.3 Hz), 170.0, 169.7, 143.6, 137.8, 128.6, 128.5, 127.8, 126.5, 123.8, 119.7, 83.3, 45.0 (d, J = 50.6 Hz), 45.0, 24.8, 24.6, 13.8.

¹¹B NMR (96 MHz, CDCl₃) δ 33.4.

(Note: Through the NMR spectra, we can clearly see that the carbonyl and methylene carbon atoms are labelled by ¹³C).




231111.f357.11.fid — ghq-p-378 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 57 — 300.20MHz



231111.f357.13.fid — ghq-p-378 — Au13C CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 57 — 75.50MHz

6.2 Deuterium labeling experiment.


6.2.1 Deuterated *trans-\beta*-methylstyrene.



(*E*)-(prop-1-en-1-yl- d_5)benzene (**1**- d_5)was synthesized according to the existed literature.⁵

¹H NMR (400 MHz, CDCl₃) δ 7.46 – 7.33 (m, 4H), 7.29 – 7.24 (m, 1H), 6.47 (dd, J = 4.5, 1.8 Hz, 0.35H), 6.31

(dddd, *J* = 10.1, 5.6, 2.5, 1.1 Hz, 0.61H), 1.96 – 1.93 (m, 1.97H).



A dried vial (4 mL) was charged with Cu(OAc)₂ (5 mol%), DPPE (5 mol%), B₂pin₂ (3.5 equiv.), and a stirring bar. When the NaOEt (2.75 equiv.) is added, the vial was sealed by PTFE/white rubber septum (Wheaton 13 mm Septa) and phenolic cap immediately. The vial was evacuated under vacuum and recharged with argon for three times with a needle. Then, (*E*)-(prop-1-en-1-yl- d_5)benzene (1- d_5) (0.2 mmol), aniline (2.5 equiv.) and DMSO (1.0 mL) were added under argon by using a syringe. The vial (or several vials) was placed in an alloy plate and transferred into a 300 mL autoclave of the 4560 series from Parr Instruments. The autoclave was charged with


CO (10 bar) after flushing two times with N_2 and two times with CO. The autoclave was then placed into an aluminum block on a magnetic stirrer. The reaction was performed for 20 h at 60 °C. After the reaction was complete, the autoclave was cooled down to room temperature and the pressure was released carefully. The reaction was quenched with water (2 mL) and extracted with EtOAc (2 mLx3). The organic layer was washed with water (10 mL) and dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. After that the corresponding product (**1a-D1**) was afforded as white solid by directly purified by fast column chromatography. (For NMR yield: The organic layer was washed with water and 0.1 mmol of 1,3,5-trimethoxybenzene was added. After drying with anhydrous Na_2SO_4 , an appropriate amount of organic layer was concentrated under reduced pressure to test the NMR yield.)


¹H NMR (300 MHz, CDCl₃) δ 7.33 – 7.22 (m, 9H), 7.04 (ddd, J = 8.5, 6.3, 2.4 Hz, 2H), 3.19 (ddt, J = 10.0, 6.8, 4.0 Hz, 1H), 2.82 (dd, J = 14.0, 3.2 Hz, 1H), 2.70 – 2.53 (m, 1H), 1.50 – 1.44 (m, 0.61H), 1.31 (d, J = 1.8 Hz, 13H), 0.82 (d, J = 6.3 Hz, 1.97H).

¹³C NMR (75 MHz, CDCl₃) δ 170.0, 143.6, 137.8, 128.7, 128.6, 127.8, 126.6, 123.9, 119.7, 83.4, 45.6, 45.2, 24.9, 24.6, 13.9 – 13.4 (m).


¹¹B NMR (96 MHz, CDCl₃) δ 33.6.

ghq-p-353 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 38 — 300.20MHz





231103.f338.12.fid — ghq-p-353 — Au13C CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 38 — 75.50MHz




A dried vial (4 mL) was charged with Cu(OAc)₂ (5 mol%), DPPE (5 mol%), B₂pin₂ (3.5 equiv.), and a stirring bar. When the NaOEt (2.75 equiv.) is added, the vial was sealed by PTFE/white rubber septum (Wheaton 13 mm Septa) and phenolic cap immediately. The vial was evacuated under vacuum and recharged with argon for three times with a needle. Then, *trans-\beta*-methylstyrene (0.2 mmol), aniline (2.5 equiv.) and DMSO- d_6 (1.0 mL) were added under argon by using a syringe. The vial (or several vials) was placed in an alloy plate and transferred into a 300 mL autoclave of the 4560 series from Parr Instruments. The autoclave was charged with CO (10 bar) after flushing two times with N₂ and two times with CO. The autoclave was then placed into an aluminum block on a magnetic stirrer. The reaction was performed for 20 h at 60 °C. After the reaction was complete, the autoclave was cooled down to room temperature and the pressure was released carefully. The reaction was quenched with water (2 mL) and extracted with EtOAc (2 mLx3). The organic layer was washed with water (10 mL) and dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. After that the corresponding product (1a-D2) was afforded as white solid by directly purified by fast column chromatography. (For NMR yield: The organic layer was washed with water and 0.1 mmol of 1,3,5-trimethoxybenzene was added. After drying with anhydrous Na₂SO₄, an appropriate amount of organic layer was concentrated under reduced pressure to test the NMR yield.) ¹H NMR (400 MHz, CDCl₃) δ 7.33 – 7.28 (m, 2H), 7.25 – 7.18 (m, 7H), 7.07 – 6.96 (m, 2H), 3.15 (td, J = 10.2, 4.1 Hz, 1H), 2.80 (dd, J = 14.0, 4.1 Hz, 1H), 2.62 (dd, J = 14.0, 10.3 Hz, 1H), 1.49 - 1.42 (m, 1H), 1.29 (d, J = 14.0, 4.1 Hz, 1H), 2.62 (dd, J = 14.0, 4.1 Hz, 1H), 1.49 - 1.42 (m, 1H), 1.29 (d, J = 14.0, 4.1 Hz, 1H), 1.49 - 1.42 (m, 1H), 1.49 (m, 1 2.4 Hz, 12H), 0.81 (d, J = 7.4 Hz, 3H).


¹³C NMR (101 MHz, CDCl₃) δ 170.0, 143.7, 137.8, 128.8, 128.6, 127.8, 126.6, 123.9, 119.7, 83.4, 45.7, 45.3, 24.9, 24.6, 14.0.


¹¹B NMR (96 MHz, CDCl₃) δ 33.3.

HRMS (ESI-TOF): calcd for [M+Na]⁺ C₂₇H₃₀¹⁰BNO₃ 401.2247, found: 401.2251.




Huiqing Geng GHQ-P-347 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 16 — 400.13MHz







A dried vial (4 mL) was charged with Cu(OAc)₂ (5 mol%), DPPE (5 mol%), B₂pin₂ (3.5 equiv.), and a stirring bar. When the NaOEt (2.75 equiv.) is added, the vial was sealed by PTFE/white rubber septum (Wheaton 13 mm Septa) and phenolic cap immediately. The vial was evacuated under vacuum and recharged with argon for three times with a needle. Then, *trans-\beta*-methylstyrene (0.2 mmol), aniline- d_7 (2.5 equiv.) and DMSO (1.0 mL) were added under argon by using a syringe. The vial (or several vials) was placed in an alloy plate and transferred into a 300 mL autoclave of the 4560 series from Parr Instruments. The autoclave was charged with CO (10 bar) after flushing two times with N₂ and two times with CO. The autoclave was then placed into an aluminum block on a magnetic stirrer. The reaction was performed for 20 h at 60 °C. After the reaction was complete, the autoclave was cooled down to room temperature and the pressure was released carefully. The reaction was quenched with water (2 mL) and extracted with EtOAc (2 mLx3). The organic layer was washed with water (10 mL) and dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. After that the corresponding product (1a-D3) was afforded as white solid by directly purified by fast column chromatography. (For NMR yield: The organic layer was washed with water and 0.1 mmol of 1,3,5-trimethoxybenzene was added. After drying with anhydrous Na₂SO₄, an appropriate amount of organic layer was concentrated under reduced pressure to test the NMR yield.) ¹H NMR (300 MHz, CDCl₃) δ 7.33 – 7.17 (m, 5H), 7.08 (s, 1H), 3.33 – 3.05 (m, 1H), 2.80 (dd, J = 14.0, 4.1 Hz, 1H), 2.67 - 2.58 (m, 1H), 1.46 (dd, J = 10.0, 7.5 Hz, 1H), 1.28 (d, J = 1.8 Hz, 12H), 0.82 (d, J = 7.4 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 170.0, 143.7, 128.6, 127.8, 126.6, 83.3, 45.6, 45.2, 24.9, 24.6, 13.9. ¹¹B NMR (96 MHz, CDCl₃) δ 33.3.



S43



6.2.4 Quenching with D₂O.





A dried vial (4 mL) was charged with Cu(OAc)₂ (5 mol%), DPPE (5 mol%), B₂pin₂ (3.5 equiv.), and a stirring bar. When the NaOEt (2.75 equiv.) is added, the vial was sealed by PTFE/white rubber septum (Wheaton 13 mm Septa) and phenolic cap immediately. The vial was evacuated under vacuum and recharged with argon for three times with a needle. Then, *trans-β*-methylstyrene (0.2 mmol), aniline (2.5 equiv.) and DMSO (1.0 mL) were added under argon by using a syringe. The vial (or several vials) was placed in an alloy plate and transferred into a 300 mL autoclave of the 4560 series from Parr Instruments. The autoclave was charged with CO (10 bar) after flushing two times with N₂ and two times with CO. The autoclave was then placed into an aluminum block on a magnetic stirrer. The reaction was performed for 20 h at 60 °C. After the reaction was complete, the autoclave was cooled down to room temperature and the pressure was released carefully. The reaction was quenched with D₂O (2 mL) and stirring for 5 minutes, then extracted with EtOAc (2 mLx3). The organic layer was washed with water (10 mL) and dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. After that the corresponding product (**1a-D4**) was afforded as white solid by directly purified by fast column chromatography. (For NMR yield: The organic layer was washed with water and 0.1 mmol of 1,3,5-trimethoxybenzene was added. After drying with anhydrous Na₂SO₄, an appropriate amount of organic layer was concentrated under reduced pressure to test the NMR yield.)

¹H NMR (300 MHz, CDCl₃) δ 7.24 – 7.09 (m, 9H), 7.01 (dd, *J* = 8.4, 2.5 Hz, 1H), 6.97 – 6.88 (m, 1H), 3.09 (td, *J* = 10.1, 4.1 Hz, 1H), 2.72 (dd, *J* = 14.0, 4.2 Hz, 1H), 2.54 (dd, *J* = 14.0, 10.2 Hz, 1H), 1.37 (dd, *J* = 9.8, 7.3 Hz, 1H), 1.20 (d, *J* = 1.9 Hz, 12H), 0.73 (d, *J* = 7.4 Hz, 3H).


¹³C NMR (75 MHz, CDCl₃) δ 170.0, 143.6, 137.8, 128.7, 128.6, 127.8, 126.6, 123.8, 119.7, 83.3, 45.6, 45.2, 24.9, 24.6, 13.9.

¹¹B NMR (96 MHz, CDCl₃) δ 33.1.





6.2.5 Additional D₂O.



A dried vial (4 mL) was charged with Cu(OAc)₂ (5 mol%), DPPE (5 mol%), B₂pin₂ (3.5 equiv.), and a stirring bar. When the NaOEt (2.75 equiv.) is added, the vial was sealed by PTFE/white rubber septum (Wheaton 13 mm Septa) and phenolic cap immediately. The vial was evacuated under vacuum and recharged with argon for three times with a needle. Then, *trans-\beta*-methylstyrene (0.2 mmol), aniline (2.5 equiv.), D₂O (0.5 equiv.) and DMSO (1.0 mL) were added under argon by using a syringe. The vial (or several vials) was placed in an alloy plate and transferred into a 300 mL autoclave of the 4560 series from Parr Instruments. The autoclave was charged with CO (10 bar) after flushing two times with N_2 and two times with CO. The autoclave was then placed into an aluminum block on a magnetic stirrer. The reaction was performed for 20 h at 60 °C. After the reaction was complete, the autoclave was cooled down to room temperature and the pressure was released carefully. The reaction was quenched with water (2 mL) and extracted with EtOAc (2 mLx3). The organic layer was washed with water (10 mL) and dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. After that the corresponding product (1a-D5) was afforded as white solid by directly purified by fast column chromatography. (For NMR yield: The organic layer was washed with water and 0.1 mmol of 1,3,5-trimethoxybenzene was added. After drying with anhydrous Na₂SO₄, an appropriate amount of organic layer was concentrated under reduced pressure to test the NMR vield.). The same procedure, but with 1.0 eq. of water, gives the product **1a-D6**. 1a-D5

¹H NMR (400 MHz, CDCl₃) δ 7.33 – 7.28 (m, 2H), 7.25 – 7.14 (m, 7H), 7.06 – 6.90 (m, 2H), 3.16 (td, *J* = 10.2, 4.0 Hz, 1H), 2.80 (dd, *J* = 14.0, 4.1 Hz, 1H), 2.62 (dd, *J* = 14.0, 10.3 Hz, 1H), 1.49 – 1.42 (m, 1H), 1.29 (d, *J* = 2.4 Hz, 12H), 0.81 (d, *J* = 7.4 Hz, 3H).


¹³C NMR (101 MHz, CDCl₃) δ 170.0, 143.7, 137.8, 128.8, 128.6, 127.9, 126.6, 123.9, 119.7, 83.4, 45.7, 45.3, 24.9, 24.7, 14.0.

1a-D6


¹H NMR (400 MHz, CDCl₃) δ 7.33 – 7.29 (m, 2H), 7.23 (t, *J* = 5.2 Hz, 7H), 7.02 (dt, *J* = 8.6, 4.2 Hz, 1H), 6.94 (s, 1H), 3.15 (td, *J* = 10.2, 4.0 Hz, 1H), 2.80 (dd, *J* = 14.1, 4.0 Hz, 1H), 2.62 (dd, *J* = 14.0, 10.3 Hz, 1H), 1.46 (dd, *J* = 10.1, 7.6 Hz, 1H), 1.29 (d, *J* = 2.3 Hz, 12H), 0.81 (d, *J* = 7.4 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 170.0, 143.7, 137.9, 128.8, 128.7, 127.9, 126.7, 124.0, 119.7, 83.5, 45.8, 45.4, 24.9, 24.7, 14.1.


¹¹B NMR (128 MHz, CDCl₃) δ 36.3.




Huiqing Geng GHQ-P-370-1 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 1 — 400.13MHz



Huiqing Geng GHQ-P-363 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 15 — 400.13MHz



6.2.6 Mixed deuterated reagents of aniline- d_7 and DMSO- d_6 .





A dried vial (4 mL) was charged with Cu(OAc)₂ (5 mol%), DPPE (5 mol%), B₂pin₂ (3.5 equiv.), and a stirring bar. When the NaOEt (2.75 equiv.) is added, the vial was sealed by PTFE/white rubber septum (Wheaton 13 mm Septa) and phenolic cap immediately. The vial was evacuated under vacuum and recharged with argon for three times with a needle. Then, *trans-β*-methylstyrene (0.2 mmol), aniline- d_7 (2.5 equiv.), and DMSO- d_6 (1.0 mL) were added under argon by using a syringe. The vial (or several vials) was placed in an alloy plate and transferred into a 300 mL autoclave of the 4560 series from Parr Instruments. The autoclave was charged with CO (10 bar) after flushing two times with N₂ and two times with CO. The autoclave was then placed into an aluminum block on a magnetic stirrer. The reaction was performed for 20 h at 60 °C. After the reaction was complete, the autoclave was cooled down to room temperature and the pressure was released carefully. The reaction was quenched with water (2 mL) and extracted with EtOAc (2 mLx3). The organic layer was washed with water (10 mL) and dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. After that the corresponding product (**1a-D7**) was afforded as white solid by directly purified by fast column chromatography. (For NMR yield: The organic layer was washed with water and 0.1 mmol of 1,3,5-trimethoxybenzene was added. After drying with anhydrous Na₂SO₄, an appropriate amount of organic layer was concentrated under reduced pressure to test the NMR yield.).

¹H NMR (300 MHz, CDCl₃) δ 7.25 (ddt, J = 15.1, 11.1, 7.1 Hz, 5H), 6.96 (s, 1H), 3.15 (dd, J = 10.0, 7.4 Hz, 1H), 1.51 – 1.40 (m, 1H), 1.29 (d, J = 1.5 Hz, 12H), 0.81 (d, J = 7.4 Hz, 3H).


¹³C NMR (75 MHz, CDCl₃) δ 170.0, 143.7, 137.7, 128.6, 127.9, 126.6, 83.4, 45.6, 24.9, 24.7, 14.0.

¹¹B NMR (96 MHz, CDCl₃) δ 33.5.






6.2.7 Mixed deuterated reagents of aniline- d_7 , DMSO- d_6 , and D₂O.



A dried vial (4 mL) was charged with Cu(OAc)₂ (5 mol%), DPPE (5 mol%), B₂pin₂ (3.5 equiv.), and a stirring bar. When the NaOEt (2.75 equiv.) is added, the vial was sealed by PTFE/white rubber septum (Wheaton 13 mm Septa) and phenolic cap immediately. The vial was evacuated under vacuum and recharged with argon for three times with a needle. Then, *trans-β*-methylstyrene (0.2 mmol), aniline- d_7 (2.5 equiv.), DMSO- d_6 (1.0 mL) and D₂O (0.5 equiv.) were added under argon by using a syringe. The vial (or several vials) was placed in an alloy plate and transferred into a 300 mL autoclave of the 4560 series from Parr Instruments. The autoclave was charged with CO (10 bar) after flushing two times with N₂ and two times with CO. The autoclave was then placed into an aluminum block on a magnetic stirrer. The reaction was performed for 20 h at 60 °C. After the reaction was complete, the autoclave was cooled down to room temperature and the pressure was released carefully. The reaction was quenched with water (2 mL) and extracted with EtOAc (2 mLx3). The organic layer was washed with water (10 mL) and dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. After that the corresponding product (**1a-D8**) was afforded as white solid by directly purified by fast column chromatography. (For NMR yield: The organic layer was washed with water and 0.1 mmol of 1,3,5-trimethoxybenzene was added. After drying with anhydrous Na₂SO₄, an appropriate amount of organic layer was concentrated under reduced pressure to test the NMR yield.).

¹H NMR (300 MHz, CDCl₃) δ 7.34 – 7.27 (m, 2H), 7.25 – 7.16 (m, 3H), 6.93 (s, 1H), 3.13 (d, *J* = 10.1 Hz, 1H), 1.46 (dd, *J* = 10.1, 7.5 Hz, 1H), 1.29 (d, *J* = 1.5 Hz, 12H), 0.81 (d, *J* = 7.4 Hz, 3H).




ghq-p-402 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 39 — 300.20MHz

7. X-ray crystal analysis of 1a.

1a


Data were collected on a Bruker Kappa APEX II Duo diffractometer. The structure was solved by direct methods (SHELXS-97: Sheldrick, G. M. *Acta Cryst.* **2008**, *A64*, 112.) and refined by full-matrix least-squares procedures on F^2 (SHELXL-2019: Sheldrick, G. M. *Acta Cryst.* **2015**, *C71*, 3.). XP (Bruker AXS) was used for graphical representations. CCDC 2283170 contains the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service www.ccdc.cam.ac.uk/structures.



Molecular structure of **1a**. Displacement ellipsoids correspond to 30% probability. The pinacol boronic esters (tetramethyl-1,3,2-dioxaborolanes or "Bpin esters" for short) unit of one molecule is disordered over two sites with occupancies of 0.675(3):0.325(3). The lower occupied unit is shown with unfilled bonds. C-bound hydrogen atoms are omitted for clarity.

Table 1. Crystallographic Details

stanographic Details	
chemical formula	$C_{23}H_{30}BNO_3$
formula weight	379.29
crystal system	triclinic
unit cell dimensions	
<i>a</i> [Å]	13.6717(12)
<i>b</i> [Å]	16.5727(14)
<i>c</i> [Å]	19.6345(17)
<i>a</i> [deg]	85.336(2)
<i>b</i> [deg]	85.800(2)
<i>g</i> [deg]	78.852(2)
<i>V</i> [Å ³]	4342.8(7)
<i>T</i> [K]	110(2)
space group	$P\overline{1}$
Ζ	8
$m [{ m mm}^{-1}]$	0.075
density [g/cm ³]	1.160
no. of reflections measured	140929
no. of independent reflections	20961 ($R_{\rm int} = 0.0378$)
no. of observed reflections $(I > 2\sigma(I))$	16120
no. of parameters	1105
$R_1 (I > 2s(I))$	0.0561
wR_2 (all data)	0.1572
Goodness of fit on F^2	1.025
largest diff. peak and hole [e/Å ³]	1.425 and -0.373



Molecular structure of one molecule of the asymmetric unit of **1a**. Displacement ellipsoids correspond to 50% probability. C-bound hydrogen atoms are omitted for clarity.

8. References.


(1) C. N. Farthing, S. P. Marsden, Tetrahedron Lett. 2000, 41, 4235-4238.

(2) R. P. Sonawane, V. Jheengut, C. Rabalakos, R. Larouche-Gauthier, H. K. Scott, V. K. Aggarwal, *Angew. Chem., Int. Ed.* **2011**, *50*, 3760-3763.


(3) M. Wang, H. Yu, X. You, J. Wu, Z. Shang, Chin. J. Chem. 2012, 30, 2356-2362.

(4) D. L. Sandrock, L. Jean-Gérard, C.-Y. Chen, S. D. Dreher, G. A. Molander, J. Am. Chem. Soc. 2010, 132, 17108-17110.


9. NMR spectra





230516.304.10.fid — Huiqing Geng GHQ-P — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2305 4 — 300.13MHz




S62










230713.308.10.fid — Huiqing Geng GHQ-P-158 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2307 8 — 300.13MHz







230815.303.10.fid — Huiqing Geng GHQ-P-219 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2308 3 — 300.13MHz














230815.304.10.fid --- Huiqing Geng GHQ-P-220 -- Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2308 4 -- 300.13MHz


















231006.304.10.fid — Huiqing Geng GHQ-P-251 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2310 4 — 300.13MHz




S78










 $230904.303.10.fid - {\tt Huiqing Geng} \ {\tt GHQ-P-205} \ - {\tt Au1H \ CDCl3} \ \{{\tt C:} {\tt Bruker} {\tt TopSpin3.6.2} \ {\tt 2309 \ 3-300.13MHz} \ {\tt 230904.303.10.fid} \ - {\tt Superior} \ {\tt Constraint} \ {\tt Constrat$




S82










230908.302.10.fid — Huiqing Geng GHQ-P-241 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2309 2 — 300.13MHz







231026.f308.10.fid — Huiqing Geng GHQ-P-278 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2310 8 — 300.20MHz














230925.305.10.fid — Huiqing Geng GHQ-P-234 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2309 5 — 300.13MHz
























231024.f312.10.fid — Huiqing Geng GHQ-P-319 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2310 12 — 300.20MHz













231024.f313.10.fid — Huiqing Geng GHQ-P-323 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2310 13 — 300.20MHz







230901.411.10.fid — Huiqing Geng GHQ-P-224 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2309 11 — 400.13MHz








231012.f303.10.fid — Huiqing Geng GHQ-P-300 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2310 3 — 300.20MHz










































231007.f360.10.fid — GHQ-P-291 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2310 60 — 300.20MHz







231012.f304.10.fid — Huiqing Geng GHQ-P-299 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2310 4 — 300.20MHz







231103.f323.11.fid — Huiqing Geng GHQ-P-344 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 23 — 300.20MHz










S128




231001.307.10.fid — Huiqing Geng, GHQ-P-255 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2310 7 — 300.13MHz












231002.319.10.fid — Huiqing Geng GHQ-P-245 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2310 19 — 300.13MHz




S134





230921.f303.10.fid — Huiqing Geng GHQ-P-246 — PROTON CDCl3 {C:\Bruker\TopSpin3.6.2} 2309 3 — 300.20MHz







230922.f302.10.fid — Huiqing Geng GHQ-P-247-2 — PROTON CDCl3 {C:\Bruker\TopSpin3.6.2} 2309 2 — 300.20MHz














231005.428.10.fid — Huiqing Geng GHQ-P-276 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2310 28 — 400.13MHz



















231124.f337.10.fid — ghq-p-398 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 37 — 300.20MHz


























S156





231101.423.10.fid — Huiqing Geng GHQ-P-431 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 23 — 400.13MHz







231106.308.10.fid — Huiqing Geng GHQ-P-352 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 8 — 300.13MHz







231005.f334.10.fid — Huiqing Geng GHQ-P-285 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2310 34 — 300.20MHz






231103.f324.11.fid — Huiqing Geng GHQ-P-325 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 24 — 300.20MHz







231114.308.12.fid — Huiqing Geng, GHQ-P-385 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 8 — 300.13MHz





S166




231106.307.10.fid — Huiqing Geng GHQ-P-361-1 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 7 — 300.13MHz













231103.f337.10.fid — ghq-p-351 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 37 — 300.20MHz







231027.f360.10.fid — GHQ-P-327 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2310 60 — 300.20MHz







231027.307.10.fid — Huiqing Geng GHQ-P-328 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2310 7 — 300.13MHz





231121.307.10.fid — Huiqing Geng GHQ-P-387 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 7 — 300.13MHz





231121.f303.10.fid — Huiqing Geng GHQ-P-390 — Au1H CDCl3 {C:\Bruker\TopSpin3.6.2} 2311 3 — 300.20MHz

